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Abstract. A divergent synthesis of cyclitol derivatives has 
been developed utilizing N-heterocyclic carbene-catalyzed 
benzoin-type cyclization of C2-symmetric dialdoses. The 
resulting inososes are versatile intermediates, which are 
readily converted into not only inositols but also amino-, 
deoxy-, O-methyl-, and C-methyl-inositols. 
 




Cyclitols, which are poly-hydroxylated cycloalkanes, 
have attracted attention, especially as building blocks 
for natural product synthesis.[ 1 ] In addition, 
interesting bioactivities of cyclitols have recently 
been reported.[2] Despite the utilities, cyclitols are not 
readily available in nature. Hence, many synthetic 
methods have been developed.[ 3 ] In addition to 
fermentative approaches,[ 4 ] various reactions have 
been applied to make cycloalkanes from oxygenated 
carbon chains, including Ferrier carbocyclization,[5] 
cyclization of malonates,[6] nitronate,[7] enolate,[8] or 
!,!-dithio carbanion,[9] Mukaiyama aldol reactions,[10] 
Horner–Wadsworth–Emmons reactions,[ 11 ] pinacol 
coupling,[ 12 ] and ring-closing metathesis,[ 13 ] 
cycloaddition,[14] and Claisen rearrangement.[15] 
The benzoin condensation, which occurs between 
two molecules of aldehydes to give !-hydroxy 
ketones,[16] is a well-known N-heterocyclic carbene 
(NHC)-catalyzed reaction.[17,18] Because the products 
are simple homo-dimeric compounds, the original 
reaction has a limited utility. Therefore, efforts have 
been made to develop the so-called cross-benzoin 
reactions. In particular, an intramolecular cross-
benzoin reaction between aldehydes and ketones[19] 
has been utilized for natural product synthesis.[20] In 
contrast, an intramolecular benzoin reaction of 
dialdehydes has been less explored,[21] probably due 
to difficulty in controlling chemoselectivity[22] and 
the lack of attention to products derived from simple 
symmetric dialdehydes.[19c,23] However, we expected 
that an intramolecular benzoin-type cyclization of 
dialdose should provide a new divergent access to a 
variety of cyclitol derivatives. 
Our strategy is based on the availability of various 
dialdoses 1 and the versatility of inososes 2 as a 
synthetic intermediate (Scheme 1). Benzoin-type 
cyclization of 1, which is available from the 
corresponding alditols, should give 2. Stereoselective 
reduction of 2 affords cyclitols 3 and epi-3. Moreover, 
other derivatives, such as amino, deoxy, and O- and 
C-methyl cyclitols 4, 5, 6, and 7 should also be 
available from 2. Herein, we report the syntheses of 































































































Scheme 1. Divergent strategy for cyclitol derivatives via 
NHC-catalyzed benzoin-type cyclization. 
Results and Discussion 
NHC-catalyzed benzoin-type cyclization of C2-symmetric 
dialdoses to give inososes 
 2 
First, tetrabenzyl dialdose 1a, which was prepared 
from D-mannitol, was subjected to an NHC-catalyzed 
benzoin-type cyclization reaction (Table 1). A THF 
solution of 1a was added to a solution of thiazolium 
salt 8[25] (Figure 1; 25 mol %) and triethylamine (20 
mol %) in THF. After stirring at rt for 4 h, TLC 
monitoring indicated that 1a was completely 
consumed, and allo-2-inosose 2a was produced as a 
single diastereomer in 19% yield after purification by 
silica gel column chromatography (entry 1).[26] The 
stereochemistry of the newly formed hydroxyl group 
was determined by the trans-diaxial coupling (J = 9.5 
Hz)[27] between the carbinol and the adjacent methine 
protons (H5 and H6; Figure 2).  
Using triazolium salt 9a[28] or 9b[29] instead of 8 
gave a complex mixture, and 2a was not obtained 
(entries 2 and 3). Because several formyl protons 
were observed in 1H NMR of the crude mixtures, it is 
speculated that aldol-type side reactions occur due to 
the basicity of the utilized NHCs. Using more acidic 
triazolium salt 9c[28] with a pentafluorophenyl group 
suppressed the side reactions, and 2a was obtained in 
58% yield after 10 h (entry 4).  
To our delight, using chiral triazolium salt 10[28] 
drastically accelerated the reaction, which was 
completed after 2.5 h even with a lower catalyst 
loading (10 mol %) and an improved yield of 2a 
(78%) (entry 5). Interestingly, when the antipode of 
10 was used as a catalyst, the reaction did not proceed, 
and 1a was recovered quantitatively after 24 h (entry 
6). 
















entry NHC"HX solvent time/h yield/%b 
1 8 25 mol % THF 4 19 
2 9a 25 mol % THF 24 <1 
3 9b 25 mol %c THF 24 <1 
4 9c 25 mol % THF 10 58 
5 10 10 mol % THF 2.5 78 
6 ent-10 25 mol % THF 24 0 (quant) 
7 10 5 mol % THF 24 39 (11) 
8 10 5 mol % MeCN 12 83 
9 10 5 mol % CH2Cl2 0.5 81 
10 10 5 mol % toluene 0.75 88 
11d 10 5 mol % toluene 1 90 
a 20 mol % of Et3N was used in entries 1–4 and 6, while 
same amount of Et3N as NHC"HX was used in entries 5 
and 7–11. b 1a was completely consumed unless the 
recovery yield is presented in parentheses. c DBU was used 










9a: Ar = Ph,
9b: Ar = Mes,
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Figure 2. Determination of the stereochemistry of inososes. 
Other solvents were tested for the reaction using 5 
mol % of 10. In acetonitrile, the reaction proceeded 
more cleanly, and 2a was obtained in a higher yield 
(83% after 12 h; entry 8) than that in THF (39% after 
24 h; entry 7). The reaction was much faster in 
dichloromethane, and 2a was obtained in 81% yield 
after 30 min (entry 9). Among the tested solvents, 
toluene gave the best results (88% yield after 45 min; 
entry 10). It is noteworthy that the reaction with 6.0-g 
1a proceeded without problems to give 5.4-g 2a 
(entry 11). 
Next, the reaction was conducted with another C2-
symmetric dialdose 1b, which was derived from L-
iditol (Scheme 2). Although the reaction with 9c gave 
2b in a moderate yield along with unidentified 
byproducts, the reaction with ent-10 (10 mol %) 
afforded myo-inosose 2b as a single diastereomer in 
86% yield. In contrast to the reaction with 1a, which 
has the opposite stereochemistry at the !-positions, 
1b and 10 had a mismatched stereochemistry, giving 
2b in 58% yield after 24 h along with 27% recovery 
of 1b. The stereochemistry of 2b was determined 
based on the coupling constant similar to that of 2a 













58% + 1b 27% recovery10: 24 h
NHC•HX 10 mol %







Scheme 2. Reaction with 1b. 
The observed stereoselectivity in the benzoin-type 
cyclization of dialdoses 1a and 1b can be explained 
as follows (Scheme 3; for simplicity, ent-1b and 10 
are considered instead of 1b and ent-10). Breslow 
intermediate A,[18] which is generated from 10 and 
dialdose 1a or ent-1b, undergoes cyclization through 
the chair conformation, where the benzyloxy group 
next to the nucleophilic enamine carbon is in the 
equatorial position to minimize A1,3 strain. The 
nucleophilic attack then occurs from the si-face of the 
aldehyde moiety, which leads to hydrogen bonding 
between the carbonyl and the hydroxy group, 
 3 
resulting in the R-configuration in the newly formed 
stereochemistry. 
The observed stereochemical outcome and match–
mismatch with 10 and ent-10 likely indicate that the 
reaction better proceeds through the Breslow 
intermediate with the Z-geometry; otherwise the 
reaction would occur from the hindered face of the 
enamine moiety. This model contradicts the Houk's 
model, where a Breslow intermediate derived from 
N-phenyl triazolylidene prefers the E-geometry in the 
transition state of a benzoin reaction.[30] Recently, 
however, Rovis' group also reported evidence of the 
Z-preference for a Breslow intermediate derived from 
N-pentafluorophenyl triazolylidene.[31] The preferred 
geometry of Breslow intermediates likely depends on 


























, R2 = H
, R2 = OBn
2a or ent-2b
 
Scheme 3. Rationale for the stereochemical outcomes of 
the reaction with 1a or 1b (ent-1b is depicted for clarity). 
The above speculation led us to envision that 
changing the protective groups alters the 
stereochemistry in the cyclization (Scheme 4). If the 
3- and 4-hydroxy groups are protected as an 
acetonide as shown in 11, the reaction should proceed 
via chair conformation B or C. In B, there are one 
repulsive 1,3-diaxial interaction and one non-
minimum A1,3 strain, while C has two repulsive 1,3-
diaxial interactions and an unfavorable bisect allylic 
conformation. If B is more stable than C, then 
inosose 12 with a hydroxy group in the S-





















































Scheme 4. Transition states B and C leading to 12 and epi-
12, respectively. 
Thus, the reaction was performed with dialdose 
11a, which has TIPSO groups at the 2- and 5-
positions with acetonide as a protective group for the 
3- and 4-hydroxy groups. As expected, with 9c as an 
NHC precursor, 12a was formed preferentially over 
epi-12a (74:26), and 12a and epi-12a were produced 
in 53% combined yield (Table 2, entry 3). With 10 or 
ent-10, the reaction was much slower, giving an 
almost 1:1 mixture of 12a and epi-12a in 13 and 7% 
combined yield, respectively (entries 1 and 2). This is 
probably because the bulky NHCs enforce the A1,3 
strain in transition state B as well as the 1,3-diaxial 
interaction in C (Scheme 4). 



























: R = TIPS
: R = Bn
: R = TBDPS  
entry 11 NHC"HX 12 yield/%a 12:epi-12b 
1 11a 10 12a 13 (61) 48:52 
2 11a ent-10 12a 7 (47) 49:51 
3 11a 9c 12a 53 (31) 74:26 
4 11b 9c 12b 30 (3) 57:43 
5 11c 9c 12c 49 (29) >99:1 
6 11c 9cc 12c 55d (4) >99:1 
a Combined yield of 12 and epi-12 determined by 1H NMR 
with Ph3CH as an internal standard. Number in parentheses 
is the recovery yield of 11. b Determined by 1H NMR of 
the crude mixture. c 20 mol %. d Isolation yield. 
The axially oriented substituents at the 2,5-
positions significantly influence the selectivity. The 
product ratio was reduced to 57:43 in the reaction 
with 11b, which has less bulky benzyloxy groups 
(entry 4), while 12c was produced with perfect 
selectivity (>99:1) when the reaction was conducted 
using 11c, which bears more bulky TBDPSO groups 
(entry 5). This observation indicates that the two 1,3-
diaxial repulsions in C are predominant over the A1,3 
strain in B (Scheme 4). Finally, using 20 mol % of 9c, 
12c was obtained in 55% yield as a single 
diastereomer (entry 6). The stereochemistry of 12c 
was determined by the NOE experiment (Figure 2). 
Stereoselective reduction of inososes to give inositols 
To selectively obtain allo- and chiro-inositols from 
2a, the conditions for stereoselective reduction were 
investigated (Table 3). Treating 2a with NaBH4 in 
methanol gave allo-insitol derivative allo-3a in 81% 
yield as a single diastereomer (entry 1). The 
stereochemistry was determined by X-ray 
crystallography. Thus, conditions to produce chiro-3a 
were examined. Although neither reduction using 
NaBH(OAc)3 nor BH3"THF produced chiro-3a, 
reduction with BH3"SMe2 gave chiro-3a as a minor 
diastereomer (entry 2). The proportion of chiro-3a in 
the product increased to 30% and 56% when 
BH3"NH3 and t-BuNH2"BH3[ 32 ] were used as a 






























: R = H
: R = TBDPS
: R = TES
2d
2f
: R = TBDMS
: R = TMS  
entry 2 H– source solvent yield dr 
1 2a NaBH4 MeOH 81%b >99:1 
2 2a BH3"SMe2 THF quant 92:8 
3 2a BH3"NH3 THF 96% 70:30 
4 2a t-BuNH2"BH3 THF 98% 44:56 
5 2c t-BuNH2"BH3 toluene 93%b 33:67 
6 2d t-BuNH2"BH3 toluene 96% 19:81 
7 2e t-BuNH2"BH3 toluene 87%c 10:90 
8 2f t-BuNH2"BH3 toluene 88% 16:84 
a Yield and dr (ratio of allo- and chiro-3a) were 
determined by 1H NMR using Ph3CH as an internal 
standard unless otherwise noted. b Isolated yield. c Isolated 
yield over two steps from 2a. 
The observed selectivity can be explained as 
follows. Hydride reduction of inososes generally 
occurs from the less hindered side,[5f] due to the 
electron-negative substituents of inosose, which 
enhances the electrophilicity of the carbonyl group 
and induces an early transition state. Consequently, 
steric hindrance becomes a controlling factor. When 
an amine–borane complex is used as a hydride source, 
its relatively low reducing ability causes a later 
transition state. Consequently, torsional strain 















Figure 3. Rationale for stereoselectivity in Table 3. 
Based on the above speculation, the !-hydroxy 
group of 2a was protected with a bulky silyl group to 
increase the torsional strain. As expected, the 
selectivity was further improved to 67–90% (entries 
5–8). The TES group gave the best result, and chiro-
3a was obtained with a high diastereoselectivity 
(90:10) in 87% yield after treatment with TBAF 
(entry 7). The two epimers were easily separated by 
silica gel column chromatography. 
A similar selectivity was observed in the reduction 
of 2b (Scheme 5). Reduction by NaBH4 occurred 
preferentially from the equatorial direction to give 
myo-3b with a slightly lower selectivity (98:2) than 
that of 2a, probably due to the reduced steric 
hindrance of the axial side. The use of L-selectride 
afforded myo-3b as a single diastereomer. Protection 
with a TES group and reduction using t-BuNH2"BH3 
























 Scheme 5. Stereoselective reduction of 2b. 
With 12c, BH3"THF was used for the reduction 
from the equatorial direction to give an allo-rich 
mixture (89:11) of 13c in 93% yield (Scheme 6). In 
contrast, NaBH4 gave the opposite selectivity, and 
reduction from the axial direction was slightly 
preferred to give a 75:25 mixture of neo- and allo-13c. 
This preference is attributable to the steric hindrance 
by the axial TBDPSO group at the !-position. 
Reduction with t-BuNH2"BH3 after TES protection 
gave neo-13c with a high diastereoselectivity 


























Scheme 6. Stereoselective reduction of 12c. 
Synthesis of other cyclitol derivatives and deprotection 
To show the utility of the inososes 2 as synthetic 
intermediates, several transformations of 2a were 
demonstrated (Scheme 7). Amino sugar 4a was 
obtained along with minor diastereomer epi-4a by 
LiAlH4/NaOMe reduction of the O-methyl oxime[33] 
derived from 2a. The stereoselectivity of the 
reduction was reversed when the O-acetyl oxime was 
reduced with NaBH4/NiCl2,[ 34 ] and epi-14a was 
obtained as a sole diastereomer after acetylation. 
Deoxygenation of 2a via thiocarbonate and 
subsequent reduction of the carbonyl group afforded 
deoxyinositol, talo-quercitol derivative 5a. The 
stereochemistries of 4a, epi-4a, and 5a were 
determined after acetylation on the basis of the 































    66% (2 steps)







































































































Scheme 7. Conversion of 2a into other derivatives. 
Treatment of 2a with the Meerwein reagent and 
subsequent reduction gave O-methylinositol, epi-D-
pinitol derivative 6a. Reaction of 2a with 
methyllithium provided C-methylinositol 7a as the 
sole diastereomer. The stereochemistry of 6a was 
confirmed by the coupling constants, while that of 7a 
was determined by NOESY after conversion into 
acetonide 16a. 
As reported with allo-3a,[24] the benzyl groups 
were easily removed. Hydrogenolysis of 2a and 
chiro-3a using Pd/C under a hydrogen atmosphere 
gave allo-2-inosose and D-chiro-inositol in 84% and 
81% yields, respectively (Scheme 8). Deprotection of 
acetonide neo-13c was reported in the literature.[12c] 
By analogy, the other compounds should be 








































Scheme 8. Deprotection of the products. 
Conclusion 
We have developed a divergent method to synthesize 
cyclitol derivatives utilizing NHC-catalyzed benzoin-
type cyclization of C2-symmetric dialdose. With 
tetrabenzyl-protected dialdose, the key for efficient 
cyclization is the chiral triazolylidene catalyst. 
Acetonide protection at the 3,4-positions inverts the 
selectivity in the cyclization of the mannitol-derived 
dialdose. In the stereoselective reduction, employing 
t-BuNH2"BH3 as a hydride source with the !-O-TES 
protection of inosose is highly effective to overcome 
the inherent preference for reduction from the axial 
direction. The inosose products are versatile 
intermediates, which can be converted into various 
cyclitol derivatives. These results testify to the 
validity of our strategy in Scheme 1. Future 
investigations include broadening the scope of the 
methodology to non-C2-symmetric dialdoses. 
Experimental Section 
General. All melting points are uncorrected. NMR (500 
and 125 MHz for 1H and 13C, respectively) was measured 
in CDCl3 unless otherwise mentioned. Chemical shifts (#) 
and coupling constants (J) are presented in parts per 
million relative to tetramethylsilane and hertz, respectively. 
Abbreviations are as follows: s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; br, broad. 13C peak 
multiplicity assignments were made based on DEPT. The 
wave numbers of maximum absorption peaks of IR 
spectroscopy are presented in cm$1. Quadrupole, double-
focusing magnetic sector, and TOF mass spectrometers 
were used for EI-, FAB-, and ESI-MS, respectively. Silica 
gel was used for column chromatography. Reactions were 
conducted under argon atmosphere unless otherwise noted. 
Materials. Triazoliums 9c, 10, and ent-10 were prepared 
as reported.[35] (COCl)2, Et3N, 2,6-lutidine, TMSCl, and 
CH2Cl2 were purchased and distilled prior to use. Other 
starting materials, reagents and solvents were purchased 
and used as supplied unless a literature for the preparation 
is cited. Commercially available anhydrous solvents were 
used as reaction solvents, except for MeOH and CH2Cl2. 
DMSO and pyridine utilized in reactions were anhydrous 
grade. 
Table 1. 2,3,4,5-Tetra-O-benzyl-D-manno-hexodialdose 
(1a): A solution of (COCl)2 (0.25 mL, 2.9 mmol) in 
CH2Cl2 (1.5 mL + 0.5 mL wash) was added to a solution of 
DMSO (0.21 mL, 2.9 mmol) in CH2Cl2 (4.5 mL) cooled at 
–78 °C. After 2 min, a solution of 2,3,4,5-tetra-O-benzyl-
D-mannitol[36] (621 mg, 1.14 mmol) in CH2Cl2 (3 mL + 1 
mL wash % 2) was added over 5 min. After 1.5 h, Et3N (1.6 
mL, 11 mmol) was added, and the mixture was stirred for 
additional 10 min before the cooling bath was removed. 
The mixture was allowed to warm to rt and concentrated in 
vacuo. The resulting white solids was suspended in a 1:1 
mixture of pentane and EtOAc (20 mL), filtered, and 
washed with the mixed solvent (20 mL % 2). The combined 
filtrate was concentrated in vacuo to give a 58:28:14 
mixture of the title compound, EtOAc, and DMSO as a 
pale yellow oil (682 mg, quant): IR (neat): 3441, 3062, 
3031, 2861, 1728, 1496, 1458, 1373, 1258, 1211, 1096, 
910, 741, 702, 602, 455, 463. 1H NMR: 4.05 (br s, 2H), 
4.12 (br s, 2H), 4.43 (d, J = 12.0, 2H), 4.51 (d, J = 11.0, 
2H), 4.60 (d, J = 11.0, 2H), 4.65 (d, J = 12.0, 2H), 7.20–
7.36 (m, 20H) 9.70 (d, J = 1.5, 2H). 13C NMR: 72.5 (CH2), 
73.7 (CH2), 80.0 (CH), 83.2 (CH), 127.9 (CH), 127.97 
(CH), 128.00 (CH), 128.1 (CH % 2), 128.3 (CH), 128.4 
(CH), 136.9 (C), 137.1 (C), 201.0 (C). FABMS m/z: 561 
 6 
(M + Na). This oil was used for the next reaction without 
further purification. 
(2S,3S,4R,5R,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-
hydroxycyclohexanone (2a) (entry 10): EtOAc was 
removed from the above mixture of 1a (174 mg, 0.290 
mmol) by evaporation with toluene (5 mL % 3), and the 
residue was dissolved in toluene (3 mL). To a suspension 
of triazolium salt 10 (6.8 mg, 0.015 mmol) in toluene (5.5 
mL), a 1% v/v solution of Et3N in toluene (0.20 mL, 0.015 
mmol) was added, and after 30 min, the above solution of 
1a was added (1.5 mL toluene wash % 2). After 45 min, the 
mixture was concentrated in vacuo, and the residue was 
purified by column chromatography (toluene/EtOAc 40/1 
to 20/1) to give the title compound (138 mg, 88%) as a 
colorless oil with [!]25D –65.1 (c 1.00, CHCl3): IR (neat): 
3472, 3032, 2924, 2878, 1736, 1636, 1497, 1458, 1366, 
1327, 1211, 1111, 910, 741, 702, 463. 1H NMR (C6D6): 
3.76 (br s, 1H), 3.86 (dd, J = 3.5, 4.0, 1H), 3.96 (dd, J = 
3.0, 9.5, 1H), 4.02 (t, J = 4.0, 1H), 4.05 (d, J = 9.5, 1H), 
4.37 (d, J = 12.0, 1H), 4.43 (d, J = 12.0, 1H), 4.50 (d, J = 
12.0, 1H), 4.55 (dd, J = 1.5, 3.0, 1H), 4.76 (br d, J = 12.0, 
3H), 4.81 (d, J = 11.5, 1H), 4.95 (d, J = 12.0, 1H), 7.31–
7.34 (m, 4H), 7.27–7.35 (m, 16H). 13C NMR: 72.6 (CH2), 
73.4 (CH2), 73.5 (CH2), 73.7 (CH2), 75.0 (CH), 76.5 (CH), 
77.7 (CH), 80.3 (CH), 82.3 (CH), 127.6 (CH), 127.72 (CH 
% 2), 127.74 (CH), 127.8 (CH), 127.9 (CH % 2), 128.29 
(CH % 2), 128.32 (CH), 128.35 (CH), 128.40 (CH), 137.5 
(C), 137.7 (C), 137.8 (C), 138.3 (C), 205.1 (C). EIMS m/z: 
538 (M+). HRMS–FAB (m/z): [M + Na]+ calcd for 
C34H34NaO6, 561.2253; found, 561.2249. The 
stereochemistry was determined based on the trans-diaxial 
coupling (J = 9.5 Hz) between 5-H and 6-H (3.96 and 4.05 
ppm, respectively) as shown in Figure 2. 
(2S,3S,4R,5R,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-
hydroxycyclohexanone (2a) (entry 11): To a solution of 
DMSO (2.2 mL, 31 mmol) in CH2Cl2 (60 mL) cooled at 
"78 °C, a solution of (COCl)2 (2.5 mL, 29 mmol) in 
CH2Cl2 (20 mL) was added over 20 min. After 2 min, a 
solution of 2,3,4,5-tetra-O-benzyl-D-mannitol (6.0 g, 11 
mmol) in CH2Cl2 (20 mL + 10 mL wash) was added over 
30 min. After 1.5 h, Et3N (10 mL, 72 mmol) was added, 
and the mixture was stirred for additional 15 min before 
the cooling bath was removed. The mixture was allowed to 
warm to rt and evaporated. The resulting white solids were 
suspended in a 1:1 mixture of pentane and EtOAc (20 mL), 
filtered, and washed with the mixed solvent (5 mL % 2). 
The combined filtrate was concentrated in vacuo to give a 
mixture of 1a and DMSO as orange oil. The oil was 
dissolved in toluene (240 mL) and added to a premixed 
suspension of triazolium salt 10 (240 mg, 0.51 mmol) and 
Et3N (80 &L, 0.58 mmol) in toluene (200 mL). After 1 h, 
the mixture was evaporated, and the residue was purified 
by column chromatography (hexane/EtOAc 3/1) to give 
the title compound (5.4 g, 90%) as a pale yellow oil. 
Scheme 2. 2,3,4,5-Tetra-O-benzyl-L-ido-hexodialdose 
(1b): The same procedure as 1a using 2,3,4,5-tetra-O-
benzyl-L-iditol[ 37 ] (331 mg, 0.611 mmol) in place of 
2,3,4,5-tetra-O-benzyl-D-mannitol gave a 71:29 mixture of 
the title compound, and DMSO as yellow oil (349 mg, 
quant). 1H and 13C NMR were identical to those 
reported.[38] This oil was used for the next reaction, without 
further purification. 
(2R,3S,4R,5S,6S)-2,3,4,5-Tetrakis(benzyloxy)-6-
hydroxycyclohexanone (2b): To a suspension of 
triazolium salt ent-10 (14 mg, 0.030 mmol) in toluene (6 
mL), a 10% v/v solution of Et3N in toluene (0.04 mL, 0.03 
mmol) was added at rt. After 30 min, 1b[38] (160 mg, 0.290 
mmol) in toluene (3 mL + 1.5 mL wash % 2) was added. 
After 18 h, the mixture was concentrated in vacuo. The 
residue was purified by column chromatography 
(toluene/EtOAc 19/1) to give the title compound (137 mg, 
86%) as a white solid of mp 159–161 °C (decomp) with 
[!]25D +24.4 (c 1.00, CHCl3): IR (KBr): 3435, 1730. 1H 
NMR: 3.42 (t, J = 9.5, 1H), 3.47 (d, J = 4.5, 1H), 3.65 (t, J 
= 9.5, 1H), 3.89 (t, J = 9.5, 1H), 4.30 (dd, J = 2.0, 9.5, 1H), 
4.37 (ddd, J = 2.0, 4.5, 9.5, 1H), 4.58 (d, J = 11.5, 1H), 
4.790 (d, J = 11.0, 1H), 4.794 (d, J = 11.0, 1H), 4.86–4.91 
(m, 3H), 4.91 (d, J = 11.5, 1H), 4.96 (d, J = 11.0, 1H) 
7.20–7.40 (m, 20H). 13C NMR: 73.5 (CH2), 75.4 (CH2), 
76.1 (CH2 % 2), 77.3 (CH), 81.4 (CH), 81.7 (CH), 83.2 
(CH), 83.6 (CH), 127.7 (CH), 127.78 (CH), 127.80 (CH), 
127.9 (CH), 128.0 (CH), 128.09 (CH), 128.13 (CH), 128.4 
(CH), 128.5 (CH), 137.0 (C), 137.9 (C), 138.0 (C), 138.1 
(C), 204.1 (C). IR, and 1H and 13C NMR were in good 
agreement with those reported.[39] 
Table 2. 3,4-O-Isopropylidene-2,5-bis-O-triethiylsilyl-D-
manno-hexodialdose (11a): To a solution of DMSO (0.19 
mL, 2.3 mmol) in CH2Cl2 (4 mL) cooled at –78 °C, a 
solution of (COCl)2 (0.21 mL, 2.5 mmol) in CH2Cl2 (2 mL 
+ 1 mL wash) was added. The resulting mixture was stirred 
for 2 min before a solution of 3,4-O-isopropylidene-2,5-
bis-O-triisopropylsilyl-D-mannitol[12c] (535 mg, 1.00 
mmol) in CH2Cl2 (3 mL + 0.5 mL wash % 2) was added 
over 5 min. After 1.5 h, Et3N (1.4 mL, 10 mmol) was 
added, and the mixture was stirred for additional 10 min. 
After addition of pentane (20 mL), the cooling bath was 
removed, and the mixture was allowed to warm to rt. The 
resulting suspension was filtered, and the filtered solids 
were washed with a 1:1 mixture of pentane and EtOAc (20 
mL % 2). The volume of combined filtrate was reduced to 
ca 10 mL by evaporation, and the resulting suspension was 
further diluted with pentane (10 mL). The whole was 
filtered, and the filtered solids were washed with the mixed 
solvent (10 mL % 2). The combined filtrate was 
concentrated in vacuo to give a 63:30:6 mixture of the title 
compound, EtOAc, and DMSO as a yellow oil (570 mg, 
98%): IR (neat): 1943, 2866, 1736, 1466, 1381, 1238, 1219, 
1153, 1107, 1072, 1045, 1015, 999, 883, 760. 1H NMR: 
1.00–1.20 (m, 42H), 1.35 (s, 6H), 4.21 (br s, 2H), 4.42 (br 
s, 2H), 9.68 (d, J = 1.5, 1H). 13C NMR: 12.2 (CH), 17.8 
(CH3), 26.9 (CH3), 76.9 (CH), 77.8 (CH), 109.8 (C), 202.7 
(CH). HRMS–ESI m/z: [M + Na]+ calcd for C27H54NaO6Si2, 
553.3351; found, 553.3352. This oil was used for the next 
reaction without further purification. 
2,5-Di-O-Benzyl-3,4-O-isopropylidene-D-manno-
hexodialdose (11b):[12c] To a solution of (COCl)2 (0.26 mL, 
3.0 mmol) in THF (3.5 mL) cooled at –19 °C, was added a 
1 M solution of DMSO in THF (3.1 mL, 3.1 mmol) at such 
a rate that the temperature did not rise above –18 °C. After 
2 min, the mixture was cooled at –78 °C and stirred for 
additional 10 min. A solution of 2,5-di-O-benzyl-3,4-O-
isopropylidene-D-mannitol[12c] (402 mg, 1.00 mmol) in 
CH2Cl2 (7 mL + 1 mL wash) was added over 5 min. After 
30 min, Et3N (1.4 mL, 10 mmol) was added. After 10 min, 
the cooling bath was removed, and the mixture was 
allowed to warm to rt. After addition of pentane (10 mL), 
the resulting suspension was filtered, and the filtered solids 
were washed with a 1:1 mixture of pentane and EtOAc (15 
mL % 2). The volume of the combined filtrate was reduced 
by evaporation to ca 10 mL, and the resulting suspension 
was further diluted with pentane (5 mL) and filtered. The 
filtered solids were washed with the mixed solvent (15 mL 
% 2). Concentration of the filtrate gave a 39:31:30 mixture 
of the title compound, DMSO, and EtOAc as a yellow oil 
(510 mg, 97%): 1H NMR: 1.36 (s, 6H), 3.87 (dd, J = 2.0, 
3.0, 1H), 3.88 (dd, J = 2.0, 3.0, 1H), 4.33 (d, J = 3.0, 1H), 
4.34 (d, J = 3.0, 1H), 4.57 (d, J = 12.0, 2H), 4.64 (d, J = 
12.0, 2H), 7.27–7.37 (m, 10H), 9.58 (d, J = 2.0, 2H). 13C 
NMR: 201.4 (C), 136.4 (CH), 128.6 (CH), 128.4 (CH), 
110.8 (C), 83.0 (CH), 77.4 (CH), 73.3 (CH2), 26.6 (CH3). 
IR (neat): 3256, 3090, 3063, 3032, 2986, 2932, 2874, 2723, 
1736, 1454, 1381, 1138, 1084, 1026, 914, 868, 810, 748. 
HRMS–ESI m/z: [M + Na]+ calcd for C23H26O6Na, 
421.1622; found, 421.1625. This oil was used for the next 
reaction without further purification. 
2,5-Bis-O-tert-butyldiphenylsilyl-3,4-O-isopropylidene-
D-manno-hexodialdose (11c):[12c] The same procedure as 
11a using 3,4-O-isopropylidene-2,5-bis-O-tert-
butyldiphenylsilyl-D-mannitol[12c] (1.02 g, 1.46 mmol) in 
place of 3,4-O-isopropylidene-2,5-bis-O-triisopropylsilyl-
D-mannitol gave a 52:37:11 mixture of the title compound, 
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EtOAc, and DMSO as a pale yellow oil (1.11 g, 98%): IR 
(neat): 3071, 3051, 2959, 2932, 2859, 1740, 1474, 1427, 
1381, 1234, 1111, 1076, 9999, 822, 760, 741. 1H NMR: 
1.07 (s, 18H), 1.30 (s, 6H), 3.75 (br s, 2H), 4.27 (br s, 2H), 
7.25–7.39 (m, 12H), 7.54–7.60 (m, 8H), 9.25 (s, 2H). 13C 
NMR: 14.2 (C), 26.8 (CH3), 76.1 (CH), 78.5 (CH), 110.1 
(C), 127.8 (CH), 127.9 (CH), 130.0 (CH), 130.2 (CH), 
132.27 (C), 132.28 (C), 135.75 (CH), 135.77 (CH), 202.0 
(CH). HRMS–ESI m/z: [M + Na]+ calcd for C41H50NaO6Si2, 
717.3038; found, 717.3028. The oil was used for the next 
reaction without further purification. 
(2S,3S,4R,5R,6S)- and (2S,3S,4R,5R,6R)-3,4-
Isopropylidenedioxy-2,5-bis(triisopropylsiloxy)-6-
hydroxycyclohexanone (12a and epi-12a) (entry 3): 
EtOAc was removed from the above mixture of 11a (212 
mg, 0.365 mmol) by evaporation with toluene (5 mL % 3), 
and the residue was dissolved in toluene (6.5 mL). To a 
suspension of triazolium salt 9c (13 mg, 0.037 mmol) in 
toluene (7 mL), a 1% v/v solution of Et3N in toluene (0.51 
mL, 0.037 mmol) was added, and after 30 min, the above 
solution of 11a was added (2 mL toluene wash). After 24 h, 
the mixture was concentrated in vacuo to give a crude 
product. The yield (53%) and diastereomeric ratio (74:26) 
of the title compounds, and the recovery yield of 11a 
(31%) were determined by integration area of 1H NMR 
signals at 4.75 (12a), 4.13 (epi-12a), and 9.67 (11a) ppm 
with Ph3CH (5.55 ppm) as an internal standard. The 
diastereomers were separated by column chromatography 
(toluene/hexane 5:1) to give 12a as a pale yellow solid of 
mp 48–50 °C with [!]25D +6.2 (c 1.0, CHCl3) and epi-12a 
as a pale yellow oil, containing ca 10% unidentified 
impurity. The stereochemistry was tentatively assigned by 
analogy with that of 12c. 
12a: IR (KBr): 3510, 2943, 2866, 1736, 1466, 1381, 1369, 
1227, 1165, 1138, 1069, 1049, 1018, 883, 864, 849, 822, 
799. 1H NMR: 1.00–1.20 (m, 42H), 1.44 (s, 3H), 1.46 (s, 
3H), 3.17 (br d, J = 7.0, 1H), 3.98 (dd, J = 2.5, 9.5, 1H), 
4.45 (dd, J = 2.0, 9.5, 1H), 4.65 (d, J = 2.5, 1H), 4.67 (dd, 
J = 3.0, 7.0, 1H), 4.75 (dd, J = 2.0, 3.0, 1H). 13C NMR: 
11.9 (CH), 12.6 (CH), 17.6 (CH3), 17.7 (CH3), 17.9 (CH3), 
18.0 (CH3), 26.8 (CH3), 27.1 (CH3), 70.2 (CH), 73.7 (CH), 
73.8 (CH), 74.2 (CH), 75.4 (CH), 112.5 (C), 207.2 (C). 
HRMS–ESI m/z: [M + Na]+ calcd for C27H54NaO6Si2, 
553.3351; found, 553.3351. 
epi-12a: IR (neat): 3507, 2943, 2870, 1736, 1466, 1381, 
1227, 1134, 1057, 1042, 1015, 883, 853, 826, 760. 1H 
NMR: 1.00–1.20 (m, 42H), 1.44 (s, 3H), 1.47 (s, 3H), 3.68 
(d, J = 8.5, 1H), 4.00 (ddd, J = 1.0, 3.0, 8.5, 1H), 4.13 (dd, 
J = 3.0, 10.0, 1H), 4.45 (d, J = 3.0, 10.0, 1H), 4.49 (t, J = 
3.0, 1H), 4.66 (dd, J = 1.0, 3.0, 1H). 13C NMR: 12.0 (CH), 
12.2 (CH), 17.5 (CH3), 17.65 (CH3), 17.68 (CH3), 17.8 
(CH3), 26.9 (CH3), 27.1 (CH3), 70.6 (CH), 73.3 (CH), 74.3 
(CH), 77.5 (CH), 80.5 (CH), 112.1 (C), 203.7 (C). HRMS–




hydroxycyclohexanone (12b and epi-12b) (entry 4): 
EtOAc was removed from the above mixture of 11b (148 
mg, 0.280 mmol) by evaporation with toluene (5 mL % 3), 
and the residue was dissolved in toluene (3.5 mL). To a 
suspension of triazolium salt 9c (10 mg, 0.028 mmol) in 
toluene (5 mL), a 1% v/v solution of Et3N in toluene (0.39 
&L, 0.028 mmol) was added, and after 30 min, the above 
solution of 11b was added (1 mL toluene wash). After 24 h, 
the mixture was concentrated in vacuo to give a crude 
product. The yield (30%) and diastereomeric ratio (57:43) 
of the title compounds, and the recovery yield of 11b (3%) 
were determined by integration area of 1H NMR signals at 
4.14 (12b), 4.26–4.33 (epi-12b, 2H), and 9.58 (11b) ppm 
with Ph3CH (5.55 ppm) as an internal standard. The 
diastereomers were separated by column chromatography 
(hexane/EtOAc 8/1 to 4/1). The stereochemistry was 
tentatively assigned by analogy with that of 12c. 
12b: a colorless oil with [!]20D –4.8 (c 1.4, CHCl3). IR 
(neat): 3464, 3090, 3063, 3032, 2986, 2932, 2874, 1736, 
1497, 1454, 1381, 1346, 1231, 1169, 1126, 1069, 1057, 
1026, 972, 910, 849, 802, 741. 1H NMR: 1.49 (s, 3H), 1.54 
(s, 3H), 3.12 (br s, 1H), 4.14 (dd, J = 2.5, 10.0, 1H), 4.38 
(d, J = 2.5, 1H), 4.41 (dd, J = 2.0, 4.0, 1H), 4.55 (dd, J = 
2.0, 10.0, 1H), 4.57 (d, J = 11.5, 1H), 4.60 (br d, J = 4.0, 
1H), 4.69 (d, J = 12.5, 1H), 4.72 (d, J = 12.5, 1H), 4.87 (d, 
J = 11.5, 1H), 7.27–7.38 (m, 10H). 13C NMR (C6D6): 26.8 
(CH3), 26.9 (CH3), 73.0 (CH2), 74.1 (CH), 74.50 (CH2), 
74.54 (CH), 75.5 (CH), 75.6 (CH), 80.0 (CH), 112.4 (C), 
127.76 (CH), 127.78 (CH), 127.9 (CH), 128.52 (CH), 
128.53 (CH), 128.6 (CH), 137.5 (C), 138.7 (C), 205.7 (C). 
HRMS–ESI m/z: [M + Na]+ calcd for C23H26O6Na, 
421.1622; found, 421.1622. 
epi-12b: a white solid of mp 121–124°C with [!]20D +11.5 
(c 1.82, CHCl3). IR (neat): 3329, 3090, 3063, 3028, 2982, 
2932, 2909, 2882, 1744, 1497, 1454, 1396, 1381, 1242, 
1219, 1180, 1150, 1123, 1096, 1049, 1022, 968, 914, 976, 
845, 795, 752, 733. 1H NMR: 1.50 (s, 3H), 1.52 (s, 3H), 
3.40 (br d, J = 6.5, 1H), 3.97 (dt, J = 8.0, 1.5, 1H), 4.20 (br 
m, 1H), 4.26–4.33 (m, 2H), 4.40 (dd, J = 1.5, 4.0, 1H), 
4.73 (d, J = 11.5, 1H), 4.74 (d, J = 11.5, 1H), 4.86 (d, J = 
11.5, 1H), 4.88 (d, J = 11.5, 1H), 7.27–7.37 (m, 8H), 7.43 
(d, J = 7.5, 2H). 13C NMR (C6D6): 26.5 (CH3), 27.2 (CH3), 
72.3 (CH2), 74.3 (CH2), 74.8 (CH), 75.7 (CH), 76.8 (CH), 
77.0 (CH), 81.8 (CH), 112.6 (C), 127.68 (CH), 127.74 
(CH), 127.9 (CH), 128.0 (CH), 128.5 (CH), 128.6 (CH), 
138.3 (C), 138.5 (C), 205.2 (C). HRMS–ESI m/z: [M + 
Na]+ calcd for C23H26O6Na, 421.1622; found, 421.1622. 
(2S,3S,4R,5R,6S)-2,5-Bis(tert-butyldiphenylsiloxy)-3,4-
isopropylidenedioxy-6-hydroxycyclohexanone (12c) 
(entry 6): EtOAc was removed from the above mixture of 
11c (367 mg, 0.474 mmol) by evaporation with toluene (5 
mL % 2), and the residue was dissolved in toluene (7.5 mL). 
To a suspension of triazolium salt 9c (34 mg, 0.095 mmol) 
in toluene (9.5 mL), a 10% v/v solution of Et3N in toluene 
(0.13 mL, 0.095 mmol) was added, and after 30 min, the 
above solution of 11c was added (1 mL toluene wash % 2). 
After 24 h, the mixture was concentrated in vacuo.to give a 
crude product (469 mg) as a yellow oil. The yield was 
estimated to be 57% by integration area of 1H NMR 
signals at 4.57–4.66 (4H) with Ph3CH (5.55 ppm) as an 
internal standard. The above oil was purified by column 
chromatography (DIOL silica gel, hexane to 
hexane/EtOAc 98:2) to give 12c (181 mg, 55%) as a white 
solid of mp 156–157°C with [!]25D +12.6 (c 3.03, CHCl3): 
IR (neat): 3510, 3071, 3051, 2954, 2932, 2893, 2859, 1732, 
1589, 1470, 1427, 1369, 1227, 1169, 1130, 1111, 1068, 
1049, 968, 937, 864, 821, 799, 753, 741, 702. 1H NMR: 
1.02 (s, 9H), 1.04 (s, 9H), 1.46 (s, 3H), 1.51 (s, 3H), 2.72 
(d, J = 7.5, 1H), 4.12 (dd, J = 8.5, 10.0, 1H), 4.59 (dd, J = 
1.5, 10.0, 1H), 4.62–4.65 (m, 2H), 4.66 (d, J = 2.5, 1H), 
7.30–7.46 (m, 12H), 7.50 (m, 2H), 7.53 (m, 2H), 7.70 (m, 
2H), 7.77 (m, 2H). 1H NMR (C6D6): 1.09 (s, 9H), 1.18 (s, 
9H), 1.41 (s, 3H), 1.45 (s, 3H), 3.02 (d, J = 7.0, 1H), 4.08 
(dd, J = 2.5, 10.0, 1H), 4.34 (dd, J = 1.0, 10.0, 1H), 4.67 (d, 
J = 3.5, 7.0, 1H), 4.60 (dd, J = 1.0, 3.5, 1H), 4.73 (d, J = 
2.5, 1H), 7.13–7.28 (m, 12H), 7.61–7.69 (m, 4H), 7.77–
7.83 (m, 2H), 7.94–7.99 (m, 2H). 13C NMR: 19.3 (C), 19.6 
(C), 26.75 (CH3), 26.85 (CH3), 26.89 (CH3), 27.1 (CH3), 
70.8 (CH), 73.6 (CH), 73.9 (CH), 74.6 (CH), 75.7 (CH), 
127.48 (CH), 127.52 (CH), 127.68 (CH), 127.79 (CH), 
129.54 (CH), 129.88 (CH), 130.01 (CH), 130.2 (CH), 
131.86 (C), 132.00 (C), 132.1 (C), 134.1 (C), 135.7 (CH), 
135.9 (CH), 136.7 (CH), 206.1 (C). HRMS–FAB m/z: [M 
+ Na]+ calcd for C41H50O6Si2Na, 717.3038; found, 
717.3033. The relative configuration was determined by 
2% nOe between 4-H and 6-H (4.34 and 4.67 ppm in C6D6, 
respectively) as shown in Figure 2. 
Table 3. (2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-
6-(tert-butyldiphenylsiloxy)cyclohexanone (2c). To a 
solution of 2a (108 mg, 0.201 mmol), imidazole (27 mg, 
0.40 mmol), and DMAP (5 mg, 0.4 mmol), in DMF (0.4 
mL) was added TBDPSCl (0.06 mL, 0.2 mmol) at rt. After 
8.5 h, TBDPSCl (0.04 mL, 0.2 mmol) was added. After 2.5 
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h, water (1 mL) was added, and the whole was extracted 
with toluene (8 mL % 3). The combined organic layers 
were washed three times with water and with brine, dried 
over Na2SO4, and evaporated under reduced pressure. The 
residue was purified by column chromatography 
(toluene/hexane 3:1 and then hexane/EtOAc 9:1) to give a 
colorless oil. The oil was dissolved in EtOAc (2 mL), and 
washed with sat aq NaHCO3 (2 mL). The aqueous layer 
was extracted with EtOAc, and the combined organic 
layers were dried over Na2SO4 and evaporated under 
reduced pressure to yield the title compound (94 mg, 60%) 
as a colorless oil with [!]25D –58.6 (c 1.35, CHCl3): IR 
(neat): 3067, 3028, 2932, 2859, 1748, 1497, 1454, 1427, 
1389, 1362, 1215, 1161, 1111, 1080, 1049, 822, 756. 1H 
NMR: 1.18 (s, 9H), 3.74 (dd, J = 3.0, 4.0, 1H), 3.79 (dd, J 
= 3.0, 4.0, 1H), 3.84 (d, J = 12.0, 1H), 3.91 (dd, J = 3.0, 
10.0, 1H), 4.08 (d, J = 3.0, 1H), 4.37 (d, J = 12.5, 1H), 
4.43 (d, J = 11.5, 1H), 4.45 (d, J = 11.5, 1H), 4.56 (d, J = 
11.5, 1H), 4.67 (d, J = 12.0, 1H), 4.69 (d, J = 12.5, 1H), 
4.74 (d, J = 10.0, 1H), 4.79 (d, J = 11.5, 1H), 7.04–7.14 (m, 
6H), 7.21–7.38 (m, 20H), 7.72–7.75 (m, 5H). 13C NMR: 
19.6 (C), 27.2 (CH3 % 3), 72.0 (CH2), 73.3 (CH2), 73.6 
(CH2), 73.9 (CH2), 75.3 (CH), 77.6 (CH), 78.0 (CH), 80.5 
(CH), 82.2 (CH), 127.21 (CH), 127.53 (CH), 127.57 (CH), 
127.59 (CH), 127.6 (CH), 127.72 (CH), 128.0 (CH), 128.2 
(CH), 128.3 (CH), 129.3 (CH), 129.4 (CH), 133.8 (C), 
134.2 (C), 136.1 (CH), 136.6 (CH), 137.8 (C), 138.0 (C), 
138.2 (C), 138.3 (C), 201.9 (C). FABMS m/z: 799 (M + 
Na), 91 (Bn). HRMS–FAB m/z: [M + Na]+ calcd for 
C50H52O6SiNa, 799.3426; found, 799.3431. 
(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-(tert-
butyldimethylsiloxy)cyclohexanone (2d): To a solution 
of 2a (106 mg, 0.197 mmol) and imidazole (74 mg, 1.1 
mmol) in DMF (1 mL) was added TBDMSCl (50 mg, 0.33 
mmol) at rt. After 4 h, TBDMSCl (50 mg, 0.33 mmol) was 
added, and the mixture was stirred for 11 h. After addition 
of water (1 mL), the whole was extracted with toluene. The 
organic layer was washed with water three times and with 
brine, dried over Na2SO4, and evaporated under reduced 
pressure. The residue was purified by column 
chromatography (hexane/EtOAc 15:1) to yield the title 
compound (118 mg, 92%) as a yellow oil with [!]25D –24.1 
(c 1.20, CHCl3): IR (neat): 3088, 3063, 3030, 2951, 2928, 
2857, 1746, 1497, 1454, 1389, 1362, 1254, 1207, 1155, 
1101, 1051, 1028, 837, 781, 737. 1H NMR: 0.05 (s, 3H), 
0.17 (s, 3H), 0.96 (s, 9H), 3.70 (dd, J = 3.0, 4.0, 1H), 3.83 
(dd, J = 3.0, 9.5, 1H), 3.85 (dd, J = 3.0, 4.0, 1H), 4.37 (d, J 
= 12.5, 1H), 4.40 (d, J = 12.5, 1H), 4.42 (dd, J = 1.0, 3.0, 
1H), 4.47 (d, J = 12.0, 1H), 4.51 (d, J = 12.0, 1H), 4.56 (d, 
J = 1.0, 9.5, 1H), 4.64 (d, J = 12.5, 1H), 4.75 (d, J = 12.5, 
1H), 4.80 (d, J = 12.0, 1H), 4.85 (d, J = 12.0, 1H), 7.07–
7.15 (m, 4H), 7.23–7.35 (m, 16H). 13C NMR: –5.2 (CH3), 
–4.7 (CH3), 18.6 (C), 25.8 (CH3 % 3), 72.4 (CH2), 73.2 
(CH2), 73.7 (CH2), 74.0 (CH2), 75.4 (CH), 77.5 (CH), 78.0 
(CH), 80.6 (CH), 81.8 (CH), 127.55 (CH), 127.63 (CH), 
127.67 (CH), 127.71 (CH), 127.8 (CH), 127.9 (C), 128.2 
(C), 128.27 (CH), 128.33 (CH), 128.34 (CH), 137.9 (C), 
138.00 (C), 138.04 (C), 138.5 (C), 203.1 (C). FABMS m/z: 
675 (M + Na), 91 (Bn). HRMS–FAB m/z: [M + Na]+ calcd 
for C40H48O6SiNa, 675.3113; found, 675.3118. 
(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-
(triethylsiloxy)cyclohexanone (2e): To a solution of 2a 
(258 mg, 0.440 mmol) and pyridine (0.14 mL, 1.8 mmol) 
in CH2Cl2 (0.8 mL), was added TESCl (0.20 mL, 0.88 
mmol) at –78 °C. After 2 h, sat aq NaHCO3 (2 mL) was 
added, and the organic layer was separated. The aqueous 
layer was extracted with toluene (2 mL % 5). The combined 
organic layers were washed with water (10 mL % 5) and 
brine (10 mL), dried over Na2SO4, and evaporated under 
reduced pressure. The residue was purified by column 
chromatography (hexane/EtOAc 96:4) to yield the title 
compound (118 mg 86%) as a colorless oil with [!]20D –
37.2 (c 0.445, CHCl3). IR (neat): 3086, 3063, 3032, 2955, 
2936, 2913, 2874, 1748, 1454, 1385, 1362, 1238, 1207, 
1157, 1111, 1084, 1053, 1026, 914, 814, 737. 1H NMR: 
0.58–0.78 (m, 6H), 0.99 (t, J = 8.0, 9H), 3.71 (dd, J = 3.0, 
4.0, 1H), 3.82 (dd, J = 3.0, 9.5, 1H), 3.86 (dd, J = 3.0, 4.0, 
1H), 4.37 (d, J = 12.0, 1H), 4.41 (d, J = 12.0, 1H), 4.43 (dd, 
J = 1.0, 3.0, 1H), 4.48 (d, J = 12.0, 1H), 4.52 (d, J = 12.0, 
1H), 4.59 (dd, J = 1.0, 9.5, 1H), 4.65 (d, J = 12.0, 1H), 
4.76 (d, J = 12.0, 1H), 4.81 (d, J = 12.0, 1H), 4.86 (d, J = 
12.0, 1H), 7.06–7.16 (m, 4H), 7.23–7.35 (m, 16H). 13C 
NMR: 4.9 (CH2), 6.8 (CH3), 72.4 (CH2), 73.2 (CH2), 73.7 
(CH2), 74.0 (CH2), 75.4 (CH), 77.5 (CH), 77.9 (CH), 80.6 
(CH), 81.9 (CH), 127.5 (CH), 127.68 (CH), 127.69 (CH), 
127.72 (CH), 127.8 (CH), 128.18 (CH), 128.24 (CH), 
128.3 (CH), 137.9 (C), 138.0 (C), 138.1 (C), 138.6 (C), 
203.1 (C). FABMS m/z: 675 (M + Na), 91 (Bn). HRMS–
ESI m/z: [M + Na]+ calcd for C40H48O6SiNa, 675.3113; 
found, 675.3118. 
(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-
(trimethylsiloxy)cyclohexanone (2f): To a solution of 2a 
(87 mg, 0.16 mmol) and Et3N (0.09 mL, 0.6 mmol) in 
CH2Cl2 (0.5 mL) was added TMSCl (0.04 mL, 0.3 mmol) 
at 0 °C. After 1.5 h, Et3N (0.05 mL, 0.3 mmol) and TMSCl 
(0.02 mL, 0.2 mmol) were added. After 1.5 h, sat aq 
NaHCO3 (4 mL) was added, and the organic layer was 
separated. The aqueous layer was extracted with EtOAc (4 
mL % 3). The combined organic layers were washed with 
water (12 mL) and brine (12 mL), dried over Na2SO4, and 
evaporated to give a crude product as a pale yellow oil: 1H 
NMR: 0.31 (s, 9H), 3.87 (dd, J = 3.0, 4.0, 1H), 4.07 (dd, J 
= 3.0, 4.0, 1H), 4.11 (dd, J = 3.0, 9.5, 1H), 4.21 (d, J = 
12.0, 1H), 4.40 (d, J = 12.0, 1H), 4.42 (d, J = 12.0, 1H), 
4.45 (d, J = 12.0, 1H), 4.62 (dd, J = 1.0, 3.0, 1H), 4.75 (d, 
J = 12.0, 1H), 4.76 (d, J = 12.0, 1H), 4.83 (d, J = 12.0, 1H), 
4.88 (dd, J = 1.0, 9.5, 1H), 4.92 (d, J = 12.0, 1H), 7.03–
7.37 (m, 20H). Remaining EtOAc was removed by 
evaporation with toluene (5 mL). The resulting pale yellow 
oil was used in the reduction without purification. 
(1R,2S,3R,4R,5R,6R)-3,4,5,6-Tetrakis(benzyloxy)cyclo-
hexane-1,2-diol (allo-3a) (entry 1): To a solution of 2a 
(38 mg, 0.071 mmol) in MeOH (0.5 mL) was added 
NaBH4 (4 mg, 0.1 mmol) at 0 °C. After 30 min, sat aq 
NaHCO3 (1 mL) was added, and the whole was extracted 
with CHCl3. The organic layer was washed with water and 
brine, dried over Na2SO4, and concentrated in vacuo. The 
residue was purified by column chromatography 
(hexane/EtOAc 3:1) to yield the title compound (31 mg, 
81%) as a colorless solid of mp 96–98 °C with [!]20D –
20.2 (c 1.00, CHCl3): IR (neat): 3441, 3063, 3028, 2874, 
1497, 1454, 1273, 1092, 1068, 1026, 910. 1H NMR 
(55 °C): 2.67 (br s, 1H), 3.47 (br s, 1H), 3.86–3.92 (br m, 
5H), 4.15 (br s, 1H), 4.50–4.70 (m, 8H), 7.20–7.35 (m, 
20H). 13C NMR: 73.2 (CH2), 77.1 (CH), 127.7 (CH), 127.8 
(CH), 127.9 (CH), 128.3 (CH), 128.36 (CH), 128.44 (CH), 
128.5 (CH), 137.9 (C), 138.4 (C). HRMS–ESI m/z: [M + 
Na]+ calcd for C34H36O6Na, 563.2405; found, 563.2404. 
Recrystallization from hexane/EtOAc provided colorless 
needles suitable for X-ray crystallographic analysis; 
monoclinic P21, a = 11.3487(9) Å, b = 7.9412(6) Å, c = 
16.2792(13) Å, ! = 90.0000°, " = 99.4718(19)°, # = 
90.0000°, Z = 2, R1 = 0.1000, wR2 = 0.1548; which 
determined the stereochemistry. CCDC-1009954 contains 
the supplementary crystallographic data of this compound. 
These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
(1S,2S,3R,4R,5R,6R)-3,4,5,6-Tetrakis(benzyloxy)cyclo-
hexane-1,2-diol (chiro-3a) (entry 7): To a solution of 2a 
(174 mg, 0.324 mmol) and pyridine (0.11 mL, 1.3 mmol) 
in CH2Cl2 (0.5 mL) was added TESCl (0.15 mL, 0.65 
mmol) at –78 °C. After 2 h, sat aq NaHCO3 (2 mL) was 
added, and the organic layer was separated. The aqueous 
layer was extracted with toluene (2 mL % 4), and the 
combined organic layers were washed with water (8 mL % 
5) and brine (8 mL), dried over Na2SO4, and evaporated 
under reduced pressure to give crude O-TES inosose 2e as 
a yellow oil (230 mg). After removal of residual EtOAc by 
evaporation with toluene (5 mL), the crude product was 
dissolved in toluene (2 mL), and t-BuNH2"BH3 (73 mg, 
0.81 mmol) was added. After 30 min, 10% HCl (4 mL) and 
EtOAc (2 mL) were added, and the mixture was vigorously 
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stirred for 2 h. The aqueous layer was separated and 
extracted with EtOAc (4 mL % 2). The combined organic 
layers were washed with sat aq NaHCO3 (12 mL) and brine 
(12 mL), dried over Na2SO4, and concentrated. The dr 
(90:10) was determined by the integration area of 1H NMR 
signals at 4.39 (chiro 2H) and 3.86–3.93 (chiro 2H + allo 
5H) ppm. The residue was purified by column 
chromatography (hexane/EtOAc 5:2 to 1:1) to yield the 
title compound (136 mg, 78%) as a colorless oil with 
[!]25D +2.0 (c 1.0, CHCl3): IR (neat): 3410, 3063, 3028, 
2916, 2870, 1493, 1454, 1273, 1096, 1057, 1026, 999, 914. 
1H NMR (55 °C): 2.52 (br s, 2H), 3.68 (br d, J = 7.0, 2H), 
3.74 (br s, 2H), 3.91 (m, 2H), 4.39 (d, J = 12.0, 2H), 4.54 
(d, J = 12.0, 2H), 4.60 (d, J = 12.0, 2H), 4.61 (d, J = 12.0, 
2H), 7.18–7.19 (m, 4H), 7.25–7.33 (m, 16H). 13C NMR: 
72.6 (CH % 2), 72.8 (CH2 % 2), 73.1 (CH2), 74.3 (CH % 2), 
78.2 (CH % 2), 127.70 (CH % 2), 127.72 (CH), 127.8 (CH), 
128.0 (CH % 2), 128.35 (CH % 2), 128.45 (CH % 2), 138.16 
(C), 138.23 (C). FABMS m/z: 563 (M + Na). HRMS–FAB 
m/z: [M + Na]+ calcd for C34H36O6Na, 563.2404; found, 
563.2411. The stereochemistry was determined after the 
conversion into D-chiro-inositol. allo-3a (16 mg, 9%) was 
also obtained as the less polar product. 
Scheme 5. (1R,2S,3S,4R,5R,6S)-3,4,5,6-Tetrakis(benzyl-
oxy)cyclohexane-1,2-diol (myo-3b): To a solution of 2b 
(20 mg, 0.037 mmol) in THF (1 mL) was added a 1 M 
solution of L-selectride in THF (0.07 mL, 0.07 mmol) at –
78 °C. After 30 min, water (1 mL) was added, and the 
mixture was allowed to warm to rt. The whole was 
extracted with EtOAc (2 mL % 3), and the combined 
organic layers were washed with brine, dried over Na2SO4, 
and concentrated. The residue was purified by column 
chromatography (hexane/EtOAc 2:1) to yield the title 
compound (18 mg, 93%) as a white solid of mp 142–
143 °C with [!]20D –22.3 (c 1.60, CHCl3). IR (neat): 3588, 
3345, 3086, 3063, 3028, 2913, 1497, 1454, 1385, 1358, 
1211, 1134, 1088, 1069, 1026, 729. 1H NMR: 2.43 (br d, J 
= 4.5, 1H), 2.52 (br s, 1H), 3.45–3.50 (m, 3H), 3.86 (t, J = 
9.5, 1H), 3.97 (t, J = 9.5, 1H), 4.20 (t, J = 2.5, 1H), 4.70 (d, 
J = 11.5, 1H), 4.71 (d, J =11.5, 1H), 4.75 (d, J = 11.0, 1H), 
4.84 (d, J = 11.0, 1H), 4.85 (d, J = 10.5, 1H), 4.91 (d, J = 
11.0, 1H), 4.92 (d, J = 10.5, 1H), 4.95 (d, J = 11.0, 1H), 
7.26–7.35 (m, 20H). 13C NMR: 69.1 (CH), 71.7 (CH), 72.7 
(CH2), 75.6 (CH2), 75.7 (CH2), 75.9 (CH2), 80.0 (CH), 81.3 
(CH), 81.6 (CH), 83.2 (CH), 127.6 (CH), 127.8 (CH), 
127.88 (CH), 127.93 (CH), 128.0 (CH), 128.36 (CH), 
128.39 (CH), 128.5 (CH), 128.6 (CH), 137.7 (C), 138.5 
(C), 138.6 (C). HRMS–ESI m/z: [M + Na]+ calcd for 
C34H36NaO6, 563.2404; found, 563.2404. The melting 
point, specific rotation, and 1H and 13C NMR were in good 
agreement with those reported (mp 140–142 °C; [!]20D –25 
(c 2.7, CHCl3)).[40] 
(1R,2R,3S,4R,5R,6S)-3,4,5,6-
Tetrakis(benzyloxy)cyclohexane-1,2-diol (scyllo-3b): To 
a solution of 2b (38 mg, 70 µmol) and imidazole (24 mg, 
0.35 mmol) in DMF (0.2 mL) cooled in an ice–water bath, 
was added TESCl (0.03 mL, 0.2 mmol). After removal of 
the cooling bath, the mixture was stirred for 2 h, and water 
(1 mL) was added to the mixture. The whole was extracted 
with ether (1 mL % 3), and the combined organic layers 
were washed with brine, dried over Na2SO4, and 
evaporated under reduced pressure. The residue was 
purified by column chromatography (hexane/EtOAc 14:1) 
to yield O-TES inosose (42 mg, 93%) as a white solid of 
mp 89–91 °C with [!]20D –40 (c 0.06, CHCl3): IR (KBr): 
3032, 2955, 2920, 2878, 1736, 1458, 1408, 1385, 1366, 
1261, 1238, 1211, 1134, 1069, 1026, 814, 737. 1H NMR: 
0.59–0.70 (m, 6H), 0.96 (t, J = 8.0, 9H), 3.48 (t, J = 10.0, 
1H), 3.61 (t, J = 10.0, 1H), 3.84 (t, J = 10.0, 1H), 4.14 (dd, 
J = 1.5, 10.0, 1H), 4.34 (dd, J = 1.5, 10.0, 1H), 7.18–7.22 
(m, 2H), 7.25–7.33 (m, 16H), 7.35–7.39 (m, 2H). 13C 
NMR: 4.9 (CH2), 6.8 (CH3), 73.2 (CH2), 75.92 (CH2), 
75.97 (CH2), 76.04 (CH2), 78.7 (CH), 81.6 (CH), 82.2 
(CH), 82.8 (CH), 82.3 (CH), 127.57 (CH), 127.62 (CH), 
127.7 (CH), 127.81 (CH), 127.83 (CH), 127.9 (CH), 128.0 
(CH), 128.1 (CH), 128.26 (CH), 128.31 (CH), 128.34 (CH), 
128.4 (CH), 137.3 (C), 138.18 (C), 138.26 (C), 202.5 (C). 
FABMS m/z: 675 (M + Na), 91 (Bn). HRMS–ESI m/z: [M 
+ Na]+ calcd for C40H48O6SiNa, 675.3113; found, 675.3112. 
To a solution of the above solid (25 mg, 38 µmol) in 
toluene (0.25 mL) was added t-BuNH2"BH3 (8 mg, 0.09 
mmol) at rt. After 1 h, 10% HCl (2 mL) and THF (2 mL) 
were added, and the mixture was vigorously stirred for 15 
min. The volume of the mixture was reduced to ca 2 mL by 
evaporation, and the mixture was extracted with EtOAc. 
The organic layer was washed with sat aq NaHCO3 and 
brine, dried over Na2SO4, and concentrated. The residue 
was purified by column chromatography (hexane/EtOAc 
2:1) to yield the title compound (16 mg, 80%) as a white 
solid of mp 120–123 °C with [!]20D –4 (c 0.1, CHCl3): IR 
(KBr): 3372, 3275, 3063, 3005, 2913, 1454, 1400, 1385, 
1354, 1261, 1126, 1088, 1069, 1053, 1022, 802, 748. 1H 
NMR: 2.53 (br s, 2H), 3.43 (br m, 2H), 3.49 (br m, 2H), 
3.58 (br m, 2H), 4.78 (d, J = 11.0, 2H), 4.88 (s, 4H), 4.92 
(d, J = 11.0, 2H), 7.26–7.33 (m, 20H). 13C NMR: 73.8, 
75.5, 75.9, 82.3, 83.1, 127.7, 127.8, 127.89, 127.94, 128.4, 
128.6, 138.3, 138.4. HRMS–ESI m/z: [M + Na]+ calcd for 
C34H36NaO6, 563.2404; found, 563.2404. 1H and 13C NMR 
were in good agreement with those reported.[12a,41] 
Scheme 6. (1R,2S,3R,4S,5S,6R)-3,6-Bis(tert-butyldi-
phenylsiloxy)-4,5-(isopropylidenedioxy)cyclohexane-
1,2-diol (allo-13c): To a solution of 12c (20 mg, 0.029 
mmol) in THF (0.5 mL) cooled in an ice-water bath, was 
added a 1 M solution of BH3"THF in THF (0.060 mL, 
0.060 mmol). After 7 h, another portion of a 1 M solution 
of BH3"THF in THF (0.015 mL, 0.015 mmol) was added. 
After 1.5 h, water (2 mL) was added, and the whole was 
extracted with EtOAc (2 mL % 3). The combined organic 
layers were washed with brine, dried over Na2SO4, and 
concentrated. The borane-derived impurities were removed 
by column chromatography (hexane/EtOAc 19:1) to yield 
a mixture of the title compound with neo-13c as a colorless 
oil (19 mg, 93%) with [!]20D $20 (c 0.74, CHCl3): IR 
(neat): 3549, 3530, 3071, 3051, 2959, 2897, 1474, 1427, 
1381, 1369, 1227, 1142, 1111, 1072, 1045, 1007, 880, 849, 
822, 795, 760. 1H NMR 1.04 (s, 9H), 1.10 (s, 9H), 1.43 (s, 
3H), 1.46 (s, 3H), 1.89 (d, J = 10.5, 1H), 2.81 (d, J = 9.0, 
1H), 3.43 (dt, J = 8.5, 3.0, 1H), 3.76 (dt, J = 10.0, 3.0, 1H), 
4.08 (dd, J = 2.0, 10.0), 4.33 (dd, J = 2.5, 10.0, 1H), 4.44 (t, 
J = 3.0, 1H), 4.71 (br t, J = 3.0, 1H), 7.30–7.50 (m, 14H), 
7.61 (m, 2H), 7.70–7.80 (m, 4H). 13C NMR: 19.2 (C), 19.4 
(C), 26.9 (CH3), 27.07 (CH3), 27.12 (CH3 % 2), 68.3 (CH), 
69.8 (CH), 72.5 (CH), 74.1 (CH), 74.4 (CH), 75.7 (CH), 
111.0 (C), 127.5 (CH), 127.6 (CH), 127.8 (CH), 127.9 
(CH), 129.8 (CH), 130.0 (CH), 130.1 (CH), 132.0 (C), 
132.7 (C), 133.4 (C), 133.6 (C), 135.7 (CH), 136.0 (CH), 
136.1 (CH), 136.5 (CH). HRMS m/z: [M + Na]+ calcd for 
C41H52NaO6Si2, 719.3195; found, 719.3195. The dr (89:11) 
was determined by the integration area of 1H NMR signals 
at 4.71 and 4.58 ppm. The stereochemistry was tentatively 
assigned as drawn. 
(1R,2R,3R,4S,5S,6R)-4,5-(Isopropylidenedioxy)-3,6-
bis(tert-butyldiphenylsiloxy)cyclohexane-1,2-diol (neo-
13c): To a solution of 12c (235 mg, 0.338 mmol) and 2,6-
lutidine (0.20 mL, 1.7 mmol) in CH2Cl2 (0.5 mL) cooled at 
–78 °C, was added TESOTf (0.23 mL, 1.0 mmol). After 
14.5 h, water (2 mL) was added, and the mixture was 
allowed to warm to rt. The aqueous layer was separated 
and extracted with CHCl3 (2 mL % 3). The combined 
organic layers were washed with water (6 mL % 3), dried 
over Na2SO4, and concentrated. The residue was purified 
by column chromatography (hexane/EtOAc 98:2) to yield 
6O-TES inosose (254 mg, 93%) as a white solid of mp 78–
80 °C with [!]20D $20.5 (c 1.00, CHCl3). IR (neat): 3075, 
3051, 2955, 2932, 3859, 2878, 1751, 1474, 1462, 1427, 
1381, 1369, 1231, 1180, 1134, 1115, 1059, 1049, 1022, 
8445, 822, 741. 1H NMR: 0.14 (q, J = 8.0, 6H), 0.61 (t, J = 
8.0, 9H), 0.99 (s, 9H), 1.10 (s, 9H), 1.41 (s, 3H), 1.47 (s, 
3H), 4.19 (dd, J = 2.5, 10.0, 1H), 4.53 (dd, J = 2.0, 10.0, 
1H), 4.58 (dd, J = 2.0, 3.5, 1H), 4.61 (d, J = 2.5, 1H), 4.64 
(d, J = 3.5, 1H), 7.29–7.45 (m, 12H), 7.59–7.64 (m, 4H), 
7.67–7.72 (m, 4H). 13C NMR: 4.0 (CH2), 6.5 (CH3), 19.3 
(C), 19.9 (C), 26.8 (CH3), 27.0 (CH3), 27.2 (CH3), 71.9 
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(CH), 74.2 (CH), 74.6 (CH), 75.4 (CH), 75.7 (CH), 112.7 
(C), 126.9 (CH), 127.3 (CH), 127.5 (CH), 127.6 (CH), 
129.0 (CH), 129.5 (CH), 129.9 (CH), 130.0 (CH), 132.3 
(C), 132.7 (C % 2), 133.1 (C), 135.9 (CH), 136.2 (CH), 
136.4 (CH), 136.6 (CH), 203.9 (C). HRMS–ESI m/z: [M + 
Na]+ calcd for C47H64NaO6Si2, 831.3903; found, 831.3903. 
To a solution of the above solid (20 mg, 25 µmol) in 
toluene (0.15 mL), was added t-BuNH2"BH3 (6 mg, 0.06 
mmol) at rt. After 30 min, the mixture was evaporated to 
give a crude material as a cloudy oil. The oil was dissolved 
in a 1:1 mixture of THF/pyridine (0.8 mL) cooled in an 
ice–water bath, HF"pyridine complex (0.2 mL) was added. 
The cooling bath was removed and the mixture was stirred 
for 45 min. The mixture was cooled in the ice–water bath, 
and the reaction was quenched by the addition of sat aq 
NaHCO3 (2 mL). The whole was extracted with EtOAc (2 
mL % 3), and the combined organic layers were washed 
with brine (6 mL), dried over Na2SO4, and concentrated in 
vacuo. The residual pyridine was removed by evaporation 
with toluene (10 mL % 2). The dr (96:4) was determined by 
the integration area of 1H NMR signals at 4.58 and 4.71 
ppm. The residue was purified by column chromatography 
(hexane/EtOAc 95:5) to give a 96:4 diastereomeric mixture 
of the title compound (17 mg, 97%) as a white solid of mp 
46?48 °C with [!]25D +20 (c 0.83, CHCl3) (lit:[12c] mp 61–
64 °C, [!]D +13.7 (c 1.0, CHCl3)): IR (neat): 3549, 3071, 
3051, 3013, 2986, 2969, 2932, 2859, 1427, 1381, 1369, 
1219, 1157, 1111, 1042, 1007, 837, 760. 1H NMR: 1.08 (s, 
18H), 1.42 (s, 9H), 3.66 (br s, 2H), 4.12 (br s, 2H), 4.58 (br 
s, 2H), 7.33–7.45 (m, 12H), 7.66 (m, 4H), 7.78 (m, 4H). 
13C NMR: 19.6 (C), 27.06 (CH3), 27.13 (CH3), 67.0 (CH), 
72.8 (CH), 74.5 (CH), 111.4 (C), 127.5 (CH), 127.7 (CH), 
129.8 (CH), 129.9 (CH), 132.6 (C), 134.1 (C), 136.0 (CH), 
136.5 (CH). EIMS m/z: 639 (M – t-Bu). 1H and 13C NMR 
were in good agreement with those reported.[12c] 
Scheme 7. (1S,2R,3R,4R,5S,6R)-2-Acetamido-3,4,5,6-
tetrakis(benzyloxy)cyclohexyl acetate (14a): To a stirred 
solution of 2a (160 mg, 0.0.299 mmol) in EtOH (1.5 mL), 
were added pyridine (0.16 mL, 2.0 mmol) and 
MeONH2"HCl (125 mg, 1.50 mmol) at rt. After 30 min, 
the solution was diluted with EtOAc, washed with H2O 
and brine, dried over Na2SO4, and concentrated in vacuo. 
From the residue, the remaining pyridine was removed by 
three-time evaporation with toluene to give crude O-
methyl oxime as a yellow oil (178 mg). 
The above oil was dissolved in THF (0.5 mL + 0.25 mL 
wash % 2) and added to a suspension of NaOMe (162 mg, 
3.00 mmol) and LiAlH4 (170 mg, 4.48 mmol) at –78 °C. 
After 30 min, the cooling bath was removed, and the 
mixture was allowed to warm up to rt. After 30 min, the 
mixture was heated at 65 °C for 30 min and then cooled to 
rt. To the mixture, H2O was dropwise added until no gas 
evolution occurred. The whole was filtered through celite, 
which was successively washed with CHCl3. The 
combined filtrate was concentrated in vacuo to give a 
crude mixture of 4a and epi-4a as a yellow oil. 
The above oil was dissolved in CH2Cl2 (3 mL), and 
pyridine (0.48 mL, 5.9 mmol), Ac2O (0.57 mL, 6.0 mmol), 
and DMAP (4 mg, 0.03 mmol) were added. The mixture 
was stirred at rt for 1.5 h and diluted with EtOAc. The 
mixture was washed with 10% HCl, H2O, sat aq NaHCO3, 
and brine, dried over Na2SO4, and concentrated in vacuo. 
The resulting oil was purified by column chromatography 
(hexane/EtOAc 3:2 to 4:6) to give the title compound (127 
mg, 68%) as a yellow oil with [!]20D  +23 (c 0.33, CHCl3): 
IR (neat): 3294, 3063, 3028, 2924, 2870, 1736, 1667, 1551, 
1524, 1497, 1454, 1373, 1234, 1103, 1072, 1026, 756. 1H 
NMR: 1.86 (s, 3H), 2.01 (s, 3H), 3.57 (dd?J = 1.5, 10.0, 
1H), 3.67 (br m, 1H), 3.71 (br m, 1H), 3.90 (dd, J = 2.5, 
10.0, 1H), 4.32 (br d, J = 12.0, 1H), 4.36–4.42 (m, 2H), 
4.45–4.57 (m, 4H), 4.67 (d, J = 12.0, 1H), 4.68 (d, J = 12.0, 
1H), 5.12 (t, J = 10.0, 1H), 5.12 (br s, 1H), 7.15–7.19 (m, 
4H), 7.25–7.36 (m, 16H). 13C NMR: 20.9 (CH3), 23.4 
(CH3), 71.8 (CH2), 73.0 (CH), 73.1 (CH2), 73.2 (CH2), 
73.5 (CH3), 73.6 (CH % 2), 75.0 (CH), 76.5 (CH), 77.2 
(CH), 127.65 (CH), 127.73 (CH), 127.8 (CH), 127.9 (CH), 
128.1 (CH), 128.31 (CH), 128.34 (CH), 128.37 (CH), 
128.43 (CH), 138.0 (C), 138.2 (C), 170.1 (C), 171.3 (C). 
HRMS–ESI m/z: [M + K]+ calcd for C38H41KNO7, 
662.2515; found, 662.2518. The stereochemistry was 
determined based on the trans-diaxial couplings of 1-H 
(5.12 ppm) with 2-H and 6-H (both J = 10 Hz) as shown in 
Scheme 7. In addition, epi-14a (vide infra) was isolated as 
a minor product (20 mg, 11%). 
(1S,2S,3R,4R,5S,6R)-2-Acetamido-3,4,5,6-
tetrakis(benzyloxy)cyclohexyl acetate (epi-14a): To a 
solution of 2a (109 mg, 0.203 mmol) in pyridine (2 mL), 
was added HONH2"HCl (71 mg, 1.0 mmol), and the 
solution was stirred at rt for 1.5 h. The solution was diluted 
with EtOAc (20 mL), washed with H2O (20 mL % 3) and 
brine, dried over Na2SO4, and concentrated in vacuo to 
give crude oxime as a pale brown oil (139 mg). 
The above oil was dissolved in CH2Cl2 (2 mL), and 
pyridine (0.33 mL, 4.1 mml), DMAP (3 mg, 0.02 mmol), 
and Ac2O (0.38 mL, 4.0 mmol) were added to the stirred 
solution cooled in an ice–water bath. The mixture was 
stirred for 1 h, and the reaction was quenched by the 
addition of H2O (10 mL). The whole was extracted with 
CHCl3 (20 mL % 3), and the combined organic layers were 
washed with brine (20 mL), dried over Na2SO4, and 
concentrated in vacuo. The residual pyridine was removed 
by three-time evaporation with toluene (10 mL % 3) to give 
crude O-acetyl oxime as a yellow oil (131 mg). 
The above oil was dissolved in EtOH (2 mL), and 
NiCl2"6H2O (97 mg, 0.41 mmol) was added. To the 
mixture cooled in an ice–water bath, NaBH4 (78 mg, 2.1 
mmol) was portion-wise added, and the cooling bath was 
removed. After 1.5 h, the mixture was cooled in an ice–
water bath, and NaBH4 (78 mg, 2.1 mmol) was portion-
wise added again. The mixture was stirred at rt for 2 h and 
diluted with EtOAc (20 mL). After addition of H2O (20 
mL), the whole was filtered through celite pad, which was 
successively washed with EtOAc. The organic layer was 
separated, and the aqueous layer was extracted with EtOAc 
(20 mL % 3). The combined organic layers were washed 
with H2O and brine, dried over Na2SO4, and concentrated 
in vacuo to give crude epi-4a as a pale yellow oil (115 mg). 
The above oil was dissolved in CH2Cl2 (2 mL), and 
pyridine (0.16 mL, 2.0 mmol), Ac2O (0.19 mL, 2.0 mmol), 
and DMAP (2 mg, 0.02 mmol) were added to the stirred 
solution cooled in an ice–water bath. After 1.5 h, the 
reaction was quenched by the addition of H2O (5 mL), and 
the whole was extracted with CHCl3 (10 mL % 3). The 
combined organic layers were dried over Na2SO4 and 
concentrated in vacuo to give crude product as a pale 
brown oil (128 mg). This oil was purified by column 
chromatography (hexane/EtOAc 2:1) to give the title 
compound (65 mg, 51%) as a colorless oil with [!]20D –
18.2 (c 1.00, CHCl3): IR (neat): 3410, 3086, 3063, 3028, 
3009, 2059, 2924, 2870, 1734, 1674, 1512, 1497, 1454, 
1431, 1369, 1323, 1234, 1099, 1053, 1026, 914, 802, 752. 
1H NMR (–20 °C): 1.81 (s, 3H), 2.04 (s, 3H), 3.78 (dd, J = 
3.0, 4.0, 1H), 3.84 (dd, J = 3.0, 11.0, 1H), 3.86 (m, 1H), 
3.94 (dd, J = 3.0, 4.5, 1H), 4.36 (d, J = 11.5, 1H), 4.46 (d, 
J = 11.0, 1H), 4.47 (d, J = 12.0, 1H), 4.52 (d, J = 12.0, 1H), 
4.62 (d, J = 12.0, 1H), 4.66 (d, J = 11.5, 1H), 4.67 (d, J = 
11.0, 1H), 4.68 (d, J = 12.0, 1H), 5.04 (ddt, J = 1.0, 9.0, 
4.5, 1H), 5.22 (dd, J = 4.0, 11.0, 1H), 6.90 (d, J = 9.0, 1H), 
7.18?7.21 (m, 4H), 7.29?7.40 (m, 16H). 13C NMR: 21.0 
(CH3), 23.4 (CH3), 48.1 (CH), 70.7 (CH2), 70.8 (CH), 71.7 
(CH), 73.0 (CH2), 73.5 (CH2), 74.1 (CH2), 74.5 (CH), 74.4 
(CH), 79.1 (CH), 127.5 (CH), 127.6 (CH), 127.7 (CH), 
127.8 (CH), 128.1 (CH), 127.6 (CH), 128.27 (CH), 128.30 
(CH), 128.32 (CH), 128.5 (CH), 137.5 (C), 137.87 (C), 
137.90 (C), 138.4 (C), 170.4 (C), 170.5 (C); FABMS m/z: 
624 (M + H), 91 (Bn). HRMS–FAB m/z: [M + H]+ calcd 
for C38H42NO7, 624.2956; found, 624.2949. The 
stereochemistry was determined based on the trans-diaxial 
coupling (J = 11.0 Hz) between 2-H and 3-H (3.84 and 
5.22 ppm, respectively) as shown in Scheme 7. 
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(1R,2R,3R,4R,5R)-2,3,4,5-Tetrakis(benzyloxy)cyclo-
hexanol (5a): To a solution of 2a (540 mg, 1.00 mmol), 
DMAP (18 mg, 0.15 mmol), and pyridine (0.28 mL, 3.5 
mmol) in CH2Cl2 (10 mL) cooled in an ice–water bath, was 
added O-phenyl chlorothioformate (0.42 mL, 3.0 mmol). 
After 2.5 h, MeOH (2 mL) was added, and the mixture was 
stirred for another 10 min and evaporated. To the residue, 
EtOAc and water were added, and the aqueous layer was 
separated and extracted 3 times with EtOAc. The 
combined organic layers were washed with brine, dried 
over Na2SO4, and concentrated under reduced pressure. To 
the resulting orange oil (1.1 g), containing O-
phenoxythiocarbonyl inosose, was used in the next 
reaction without purification. The crude inosose was 
purified by column chromatography (hexane/EtOAc 95:5) 
to provide a pale yellow solid of mp 88–90 °C with [!]20D 
–53.0 (c 1.21, CHCl3): IR (neat): 3086, 3063, 3028, 2920, 
2874, 1751, 1589, 1493, 1454, 1362, 1285, 1223, 1207, 
1107, 1049, 1045, 1026, 1003, 914, 864, 818, 752. 1H 
NMR: 3.82 (dd, J = 3.0, 4.0, 1H), 3.93 (dd, J = 3.0, 4.0, 
1H), 4.19 (dd, J = 3.0, 11.0, 1H), 4.40 (d, J = 12.0, 1H), 
4.43 (d, J = 12.0, 1H), 4.50 (d, J = 12.0, 1H), 4.53 (d, J = 
12.0, 1H), 4.62 (d, J = 3.0, 1H), 4.71 (d, J = 12.0, 1H), 
4.73 (d, J = 12.0, 1H), 4.78 (d, J = 12.0, 1H), 4.78 (d, J = 
12.0, 1H), 4.90 (d, J = 12.0, 1H), 6.15 (d, J = 11.0, 1H), 
7.09–7.44 (m, 25H). 13C NMR: 72.8 (CH2), 73.7 (CH2), 
73.8 (CH2), 73.9 (CH2), 74.9 (CH), 77.5 (CH), 78.8 (CH), 
80.9 (CH), 85.6 (CH), 121.9 (CH), 126.6 (CH), 127.76 
(CH), 127.78 (CH), 127.83 (CH), 127.90 (CH), 127.98 
(CH), 128.3 (CH), 128.4 (CH), 128.5 (CH), 129.5 (CH), 
137.5 (C), 137.7 (C), 153.6 (C), 194.8 (C), 197.0 (C). 
FABMS m/z: 697 (M + Na), 91 (Bn). HRMS–ESI m/z: [M 
+ Na]+ calcd for C41H38O7SNa, 697.2231; found, 697.2233. 
To a solution of the above crude material in toluene (10 
mL), were added Bu3SnH (0.40 mL, 1.5 mmol) and AIBN 
(16 mg, 0.097 mmol), and the solution was heated at 80 °C. 
After 2 h, another portion of AIBN (16 mg, 0.097 mmol) 
was added. After 1.5 h, AIBN (16 mg, 0.097 mmol) and 
Bu3SnH (0.40 mL, 1.5 mmol) were added again. After 1 h, 
the mixture was evaporated, and the resulting yellow oil 
was purified by column chromatography (hexane to 
hexane/EtOAc 95:5) to yield deoxyinosose (345 mg, 66% 
in 2 steps) as a pale yellow oil with [!]20D –61.3 (c 0.45, 
CHCl3): IR (neat): 3086, 3063, 3028, 2924, 2870, 1732, 
1496, 1454, 1366, 1327, 1312, 1265, 1215, 1111, 1026, 
1003, 914, 802, 752. 1H NMR: 2.75 (ddd, J = 1.5, 5.0, 13.0, 
1H), 2.84 (dd, J = 11.0, 13.0, 1H), 3.93 (ddd, J = 1.5, 2.5, 
5.0, 1H), 3.99 (dd, J = 3.5, 5.0, 1H), 4.06 (ddd, J = 2.5, 5.0, 
11.0, 1H), 4.431 (d, J = 12.0, 1H), 4.433 (d, J = 3.5, 1H), 
4.44 (d, J = 12.0, 1H), 4.47 (d, J = 12.0, 1H), 4.52 (d, J = 
12.0, 1H), 4.55 (d, J = 12.0, 1H), 4.74 (d, J = 12.0, 1H), 
4.75 (d, J = 12.0, 1H), 4.87 (d, J = 12.0, 1H), 7.16–7.19 (m, 
4H), 7.27–7.37 (m, 16H). 13C NMR: 42.2 (CH2), 71.4 (CH), 
72.6 (CH), 73.4 (CH), 73.5 (CH), 75.72 (CH), 75.75 (CH), 
78.1 (CH), 81.5 (CH), 127.5 (CH), 127.68 (CH), 127.73 
(CH), 127.76 (CH), 127.79 (CH), 128.31 (CH), 128.38 
(CH), 128.42 (CH), 137.8 (C), 138.0 (C), 138.05 (C), 
138.14 (C), 204.6 (C). HRMS–ESI m/z: [M + Na]+ calcd 
for C34H34O5Na, 545.2299; found, 545.2299. 
To a solution of the above oil (9.0 mg, 17 µmol) in MeOH 
(0.2 mL) cooled in an ice–water bath, was added NaBH4 
(1.7 mg, 45 µmol), and the mixture was stirred for 40 min. 
After addition of sat aq NH4Cl, the whole was extracted 
with EtOAc (1.5 mL % 4). The combined organic layers 
were washed with brine (4.5 mL) and evaporated. The 
residue was purified by column chromatography 
(hexane/EtOAc 9:2) to give the title compound (8.3 mg, 
93%) as a pale yellow solid of mp 91–92.5 °C with [!]20D 
–24 (c 0.30, CHCl3): IR (KBr): 3314, 3086, 3063, 3028, 
2955, 2928, 2855, 2878, 2758, 2739, 2677, 1496, 1454, 
1435, 1315, 1261, 1207, 1150, 1099, 1084, 1065, 1026, 
1084, 914, 868, 802, 745. 1H NMR (60 °C): 1.85–1.95 (br 
s, 1H), 1.98 (ddd, J = 3.5, 7.5, 11.5, 1H), 3.86–3.88 (m, 
2H), 3.95 (dd, J = 2.5, 7.5, 1H), 3.97 (br s, 1H), 4.09 (br s, 
1H), 4.55–4.72 (m, 7H), 4.77 (br s, 1H), 7.21–7.35 (m, 
20H). 13C NMR: 32.4 (CH2), 71.5 (CH2), 72.5 (CH % 3), 
73.0 (CH2), 73.9 (CH2), 79.4 (CH % 2), 127.6 (CH), 127.66 
(CH), 127.72 (CH), 127.8 (CH), 127.9 (CH), 128.39 (CH), 
128.41 (CH), 128.49 (CH), 128.51 (CH), 138.7 (C), 138.8 
(C), 138.9 (C). HRMS–ESI m/z: [M + Na]+ calcd for 
C34H36O5Na, 547.2455; found, 547.2453. The 
stereochemistry was determined at the stage of 15a. 
(1R,2R,3S,4R,5R)-2,3,4,5-Tetrakis(benzyloxy)cyclohexyl 
acetate (15a): To a solution of 5a (5.9 mg, 11 µmol), 
DMAP (1 mg, 8 µmol), and Et3N (0.01 mL, 0.07 mmol) in 
CH2Cl2 (0.1 mL) cooled in an ice–water bath, was added 
Ac2O (0.01 mL, 0.1 mmol), and the mixture was stirred for 
1 h. After addition of water (2 mL), the whole was 
extracted three times with CHCl3. The combined organic 
layers were washed with brine, dried over Na2SO4, and 
concentrated in vacuo. The residue was purified by column 
chromatography (hexane/EtOAc 95:5) to give the title 
compound (4.0 mg, 64%) as a pale yellow oil with [!]20D ?
3.9 (c 1.00, CHCl3): IR (neat): 3088, 3063, 3030, 2933, 
2903, 2868, 1738, 1497, 1454, 1368, 1346, 1240, 1207, 
1159, 1094, 1070, 1051, 1026, 735. 1H NMR (60 °C): 
1.93–2.05 (m, 2H), 1.97 (s, 3H), 3.91–3.94 (m, 2H), 3.98 
(dd, J = 2.5, 9.0, 1H), 4.12 (br m, 1H), 4.64 (d, J = 11.5, 
1H), 4.66 (s, 2H), 4.69 (d, J = 11.5, 1H), 4.71 (d, J = 11.5, 
1H), 4.76 (d, J = 11.5, 1H), 4.81 (d, J = 11.5, 1H), 5.12 
(ddd, J = 2.5, 4.0, 11.0, 1H). 13C NMR: 21.3 (CH3), 28.4 
(CH2), 69.9 (CH), 71.6 (CH2), 72.5 (CH), 73.0 (CH2), 73.3 
(CH2 % 2), 74.4 (CH2), 76.9 (CH), 79.1 (CH), 79.4 (CH), 
127.45 (CH), 127.49 (CH), 127.54 (CH), 127.7 (CH), 
127.82 (CH), 127.84 (CH), 128.27 (CH), 128.33 (CH), 
128.4 (CH), 138.6 (C), 139.0 (C), 139.1 (C), 139.2 (C), 
170.6 (C). HRMS–ESI m/z: [M + K]+ calcd for C36H36KO6, 
605.2300; found, 605.2300. The stereochemistry was 
determined based on the coupling constant (2.5, 4.0, and 
11.0 Hz) of the methine proton that the AcO group attaches 
on, indicating equatorial orientation of the AcO group and 
axial orientation of the adjacent BnO groups, as shown in 
Scheme 7. 
(1R,2R,3R,4R,5R,6S)-2,3,4,5-Tetrakis(benzyloxy)-6-
methoxycyclohexanol (6a): To a solution of 2a (107 mg, 
0.198 mmol) and proton sponge (85 mg, 0.040 mmol) in 
CH2Cl2 (2 mL), was added Me3O"BF4 (59 mg, 0.40 mmol) 
at rt. After 14 h, water (8 mL) was added, and the whole 
was extracted with CHCl3 (8 mL % 2). The combined 
organic layers were washed with brine (16 mL), dried over 
Na2SO4, and concentrated under reduced pressure. The 
residue was purified by column chromatography 
(hexane/EtOAc 5:1) to yield O-Me inosose (103 mg, 90%) 
as a colorless oil with [!]20D –39.0 (c 1.00, CHCl3): IR 
(neat): 3395, 3086, 3062, 3028, 3086, 3005, 2920, 2873, 
1959, 1871, 1743, 1654, 1543, 1497, 1454, 1385, 1366, 
1323, 1026, 1150, 1111, 1026, 957, 918, 737. 1H NMR: 
3.58 (s, 3H), 3.75 (dd, J = 3.5, 4.0, 1H), 3.88 (dd, J = 3.0, 
4.0, 1H), 3.90 (dd, J = 3.5, 10.0, 1H), 4.18 (dd, J = 1.0, 
10.0, 1H), 4.36 (d, J = 12.0, 1H), 4.43 (d, J = 12.0, 1H), 
4.48 (dd, J = 1.0, 3.0, 1H), 4.49 (d, J = 12.0, 1H), 4.68 (d, 
J = 12.0, 1H), 4.73 (d, J = 12.0, 1H), 4.80 (d, J = 12.0, 1H), 
4.88 (d, J = 12.0, 1H), 7.08–7.16 (m, 4H), 7.25–7.36 (m, 
16H). 13C NMR: 59.9 (CH3), 72.5 (CH2), 73.3 (CH2), 73.7 
(CH2), 74.0 (CH2), 75.3 (CH), 77.2 (CH), 80.6 (CH), 80.7 
(CH), 85.7 (CH), 127.6 (CH), 127.71 (CH), 127.73 (CH), 
127.8 (CH), 127.9 (CH), 128.2 (CH), 128.3 (CH), 128.4 
(CH), 137.7 (C), 137.8 (C), 137.9 (C), 138.5 (C), 202.8 (C). 
FABMS m/z: 575 (M + Na), 329, 136, 91 (Bn). HRMS–
FAB m/z: [M + Na]+ calcd for C35H36O6Na, 575.2404; 
found, 575.2415. 
To a solution of the above oil (9.7 mg, 0.018 mmol) in 
MeOH (0.2 mL) cooled in an ice–water bath, was added 
NaBH4 (2 mg, 0.05 mmol). After 30 min, sat aq NH4Cl 
(1.5 mL) was added, and the whole was extracted with 
EtOAc (1.5 mL % 5). The combined organic layers were 
washed with brine (8 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was 
purified by column chromatography (hexane/EtOAc 2:1) 
to yield the title compound (8.4 mg, 86%) as a colorless oil 
with [!]20D –13 (c 0.42, CHCl3): IR (neat): 3502, 3086, 
3063, 3028, 3086, 3009, 2924, 2874, 1497, 1454, 1358, 
1261, 1215, 1092, 1041, 1026, 910, 802, 748. 1H NMR (–
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20 °C): 3.50 (dd, J = 2.5, 10.0, 1H), 3.57 (s, 3H), 3.64 (br s, 
1H), 3.66 (br s, 1H), 3.77 (br s, 1H), 3.94 (dd, J = 2.0, 10.0, 
1H), 4.34 (d, J = 12.0, 1H), 4.37 (d, J = 12.0, 1H), 4.45 (d, 
J = 12.0, 1H), 4.47 (br s, 1H), 4.52 (d, J = 12.0, 1H), 4.58 
(d, J = 12.0, 1H), 4.63 (d, J = 12.0, 1H), 4.68 (d, J = 12.0, 
1H), 4.82 (d, J = 12.0, 1H), 7.05–7.45 (m, 20H). 13C NMR 
(–20 °C): 58.0 (CH3), 68.6 (CH), 70.4 (CH2), 72.9 (CH), 
73.2 (CH2), 73.6 (CH2 % 2), 74.8 (CH), 75.7 (CH), 77.8 
(CH), 79.8 (CH), 127.5 (CH), 127.6 (CH), 127.69 (CH), 
127.78 (CH), 127.84 (CH), 127.9 (CH), 128.0 (CH), 
128.29 (CH), 128.34 (CH), 128.4 (CH), 137.0 (C), 137.8 
(C), 137.9 (C), 138.7 (C). HRMS–ESI m/z: [M + Na]+ 
calcd for C35H38O6Na, 577.2561; found, 577.2568. The 
stereochemistry was determined based on the trans-diaxial 
coupling (J = 10.0 Hz) between 5-H and 6-H (3.94 and 
3.50 ppm, respectively) as shown in Scheme 7. 
(1R,2R,3R,4R,5S,6S)-3,4,5,6-Tetrakis(benzyloxy)-1-
methylcyclohexane-1,2-diol (7a): A 1.5 M solution of 
MeLi"LiBr in THF (0.23 mL, 0.35 mmol) was diluted with 
Et2O (0.4 mL) and cooled at –78 °C. A solution of 2a (62 
mg, 0.12 mmol) in Et2O (0.4 mL + 0.2 mL wash % 2) was 
added, and the cooling bath was replaced with an ice–
water bath. After 2 h, sat aq NH4Cl (2 mL) was added, and 
the whole was extracted with EtOAc (2 mL % 4). The 
combined organic layers were washed with brine (8 mL), 
dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column 
chromatography (hexane/EtOAc 3:1 to 2:1) to yield the 
title compound (57 mg, 89%) as a colorless oil with [!]20D 
+15.8 (c 1.00, CHCl3): IR (neat): 3483, 3086, 3063, 3028, 
3005, 2982, 2932, 2870, 1956, 1871, 1655, 1605, 1543, 
1497, 1420, 1385, 1366, 1331, 1250, 1207, 1142, 1099, 
1065, 1026, 964, 914, 802, 748. 1H NMR: 1.34 (s, 3H), 
2.41 (br s, 1H), 3.49 (br s, 1H), 3.60–3.78 (m, 4H), 3.82 (br 
s, 1H), 4.43–4.42 (m, 2H), 4.45–4.63 (m, 5H), 4.71 (d, J = 
12.0, 1H), 7.09–7.19 (m, 4H), 7.23–7.39 (m, 16H). 13C 
NMR: 22.1 (CH3), 72.9 (CH2), 73.1 (CH2), 73.2 (CH2), 
73.7 (CH2), 74.2 (CH % 2), 76.4 (CH), 77.2 (CH), 77.9 
(CH), 99.8 (C), 127.6 (CH), 127.7 (CH), 127.9 (CH), 128.0 
(CH), 128.1 (CH), 128.35 (CH), 128.4 (CH), 128.5 (CH), 
137.1 (C), 137.7 (C), 138.2 (C), 138.5 (C). FABMS m/z: 
577 (M + Na), 525, 481, 437, 393, 349, 305, 243, 183, 91 
(Bn). HRMS–FAB m/z: [M + Na]+ calcd for C35H36O6Na, 
577.2561; found, 577.2565. The stereochemistry was 
determined at the stage of 16a. 
(1R,2R,3R,4R,5S,6S)-3,4,5,6-Tetrakis(benzyloxy)-1,2-
isopropylidenedioxy-1-methylcyclohexane (16a): To a 
solution of 7a (66 mg, 0.12 mmol) in 2,2-
dimethoxypropane (2.0 mL, 16 mmol) was added 
TsOH"H2O (5 mg, 0.03 mmol) at rt. The mixture was 
stirred for 2 h, and sat aq NaHCO3 (10 mL) was added. 
The whole was extracted with EtOAc (10 mL % 3), and the 
combined organic layers were washed with brine (30 mL), 
dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column 
chromatography (hexane/EtOAc 96:4) to yield the title 
compound (51 mg, 93%) as a colorless oil with [!]25D –
27.2 (c 1.44, CHCl3): IR (neat): 3086, 3062, 3028, 3005, 
2982, 2932, 2889, 2878, 1497, 1454, 1377, 1308, 1258, 
1242, 1211, 1188, 1115, 1088, 1072, 1026, 984, 918, 864, 
752, 733. 1H NMR: 1.36 (s, 3H), 1.38 (s, 3H), 1.39 (s, 3H), 
3.65 (d, J = 3.0, 1H), 3.87 (dd, J = 3.0, 6.5, 1H), 4.08 (d, J 
= 5.0, 1H), 4.10 (dd, J = 3.5, 6.5, 1H), 4.19 (dd, J = 3.5, 
5.0, 1H), 4.57 (s, 2H), 4.65 (d, J = 12.0, 1H), 4.67 (d, J = 
12.0, 1H), 4.68 (d, J = 12.0, 1H), 4.72 (d, J = 12.0, 1H), 
4.74 (d, J = 12.0, 1H), 4.76 (d, J = 12.0, 1H), 7.23–7.37 (m, 
20H). 13C NMR: 26.0 (CH3), 27.0 (CH3), 27.6 (CH3), 72.3 
(CH2), 72.89 (CH2), 72.92 (CH2), 74.7 (CH2), 76.5 (CH), 
76.9 (CH), 77.2 (CH), 81.0 (CH), 81.2 (C), 82.2 (CH), 
109.7 (C), 127.31 (CH), 127.32 (CH), 127.34 (CH), 127.36 
(CH), 127.49 (CH), 127.52 (CH % 2), 127.57 (CH), 128.07 
(CH), 128.11 (CH), 128.15 (CH), 128.18 (CH), 138.6 (C % 
2), 138.70 (C), 138.77 (C). FABMS m/z: 617 (M + Na), 
329, 176, 91 (Bn). HRMS–FAB m/z: [M + Na]+ calcd for 
C38H42NaO6, 617.2874; found, 617.2873. The relative 
configuration was determined by NOESY correlation 
between angular CH3 (1.36 ppm) and H (4.05 ppm) as 
shown in Scheme 7. 
Scheme 8. (2R,3S,4R,5S,6S)-2,3,4,5,6-pentahydroxy-
cyclohexanone (allo-2-inosose): To a solution of 2a (819 
mg, 1.52 mmol) in MeOH (10 mL), was added 10% Pd/C 
(wetted with 55% water, 485 mg, 0.20 mmol), and the 
mixture was stirred under H2 atmosphere at rt for 24 h. 
After addition of H2O (10 mL) and activated charcoal (500 
mg), the mixture was stirred for 20 min and filtered 
through filter paper, which was washed with H2O (10 mL 
% 3). The combined filtrate was concentrated in vacuo to 
give the title compound (228 mg, 84%) as colorless blocks 
of mp 180–182 °C (H2O/i-PrOH) with [!]20D +75.1 (c 1.04, 
H2O) (lit:[42] mp 195–197 °C, [!]20D +68.6 (c 1, H2O)): 1H 
NMR (DMSO-d6): 3.56 (br m, 1H), 3.82 (br s, 1H), 3.92 
(br s, 1H), 4.15 (br d, J = 6.5, 1H), 4.39 (br s, 1H), 4.71 (br 
s, 1H), 4.91 (br s, 1H), 5.00 (br s, 1H), 5.10 (br s, 1H), 5.28 
(br s, 1H). 13C NMR (DMSO-d6): 71.1 (CH), 73.3 (CH), 
73.6 (CH), 74.2 (CH), 75.7 (CH), 208.0 (C). HRMS–ESI 
m/z: [M + Na]+ calcd for C6H10NaO6, 201.0370; found, 
201.0378. 1H and 13C NMR were in good agreement with 
those reported.[42] 
D-chiro-Inositol: To a solution of chiro-3a (195 mg, 0.362 
mmol) in MeOH (2 mL), was added 10% Pd/C (wetted 
with 55% water, 193 mg, 0.0819 mmol), and the mixture 
was stirred under H2 atmosphere at rt for 10 h. After 
addition of H2O (5 mL), the whole was filtered through 
filter paper, which was washed with H2O (5 mL % 3). The 
combined filtrate was concentrated in vacuo to give the 
title compound (53 mg, 81%) as a slightly brown solid of 
mp 231–235 °C (H2O/EtOH) with [!]20D +65.2 (c 1.05, 
H2O) (lit: [!]24D +85.5 (c 0.1, H2O);[5f] mp 238–242 °C, 
[!]20D = +63.2 (c 1, H2O)[42]): 1H NMR (D2O): 3.52 (m, 
2H), 3.70 (m, 2H), 3.96 (br s, 2H). 13C NMR (D2O): 71.0 
(CH), 72.3 (CH), 73.3 (CH). HRMS–ESI m/z: [M + Na]+ 
calcd for C6H12NaO6, 203.0526; found, 203.0532. 1H and 13C NMR were in good agreement with those reported.[5f,42] 
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